Dexamethasone

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Crohn's Disease, Ulcerative Colitis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

This page stands for the molecule. Studies that name only the molecule, and no branded product, are listed here and are marked as studies of the molecule. A study of a branded product is on that product's page.

Phase 3 (530)
Crohn's Disease
NCT01277289 · Quince Therapeutics S.p.A.
2009-06-03 – 2012-06 · Crohn's Disease
What this study did
Other / comorbidity
NCT07903506 · Kite, A Gilead Company
2027-02 – 2042-03 · Newly Diagnosed Multiple Myeloma
What this study did
NCT07887672 · Kite, A Gilead Company
2027-01 – 2042-02 · Newly Diagnosed Multiple Myeloma
What this study did
NCT04381936 · University of Oxford
2020-03-19 – 2038-09-30 · Pneumonia
What this study did
NCT07624513 · Dana-Farber Cancer Institute
2026-08-31 – 2038-03-01 · Multiple Myeloma
What this study did
NCT06187441 · Stichting Hemato-Oncologie voor Volwassenen Nederland
2024-05-14 – 2037-12 · Multiple Myeloma
What this study did
NCT06932562 · European Myeloma Network B.V.
2025-12-23 – 2036-12 · Multiple Myeloma
What this study did
NCT06918002 · Intergroupe Francophone du Myelome
2025-07-09 – 2036-05 · Multiple Myeloma, Newly Diagnosed
What this study did
NCT03020030 · Dana-Farber Cancer Institute
2017-03-03 – 2034-11 · Acute Lymphoblastic Leukemia, Pediatric
What this study did
NCT03007147 · Children's Oncology Group
2017-08-08 – 2034-09-30 · Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
What this study did
NCT07222761 · Regeneron Pharmaceuticals
2026-01-02 – 2034-08-23 · Relapsed and/or Refractory Multiple Myeloma (RRMM)
What this study did
NCT07285239 · PrECOG, LLC.
2026-12 – 2034-06 · Multiple Myeloma
What this study did
NCT07764978 · AstraZeneca
2026-06-26 – 2034-05-12 · Newly Diagnosed Multiple Myeloma
What this study did
NCT01863550 · ECOG-ACRIN Cancer Research Group
2013-12-06 – 2034-02-05 · Plasma Cell Myeloma
What this study did
NCT04270409 · Sanofi
2020-06-16 – 2033-10-21 · Plasma Cell Myeloma
What this study did
NCT04307576 · Mats Heyman
2020-07-13 – 2033-06 · Leukemia, Acute Lymphoblastic
What this study did
NCT07555938 · Hoffmann-La Roche
2026-06-23 – 2033-01-31 · Multiple Myeloma
What this study did
NCT04483739 · European Myeloma Network B.V.
2020-09-25 – 2032-12-31 · Multiple Myeloma
What this study did
NCT06824467 · Merck Sharp & Dohme LLC
2025-04-09 – 2032-11-09 · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
What this study did
NCT06182774 · Canadian Cancer Trials Group
2024-04-10 – 2032-07-31 · Multiple Myeloma
What this study did
NCT06615479 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
2025-03-12 – 2032-06-22 · Relapsed or Refractory Multiple Myeloma (RRMM)
What this study did
NCT03959085 · Children's Oncology Group
2019-10-31 – 2032-03-31 · B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia, Testicular Leukemia
What this study did
NCT02845882 · Children's Cancer Group, China
2016-01 – 2031-12 · Lymphoblastic Lymphoma
What this study did
NCT07772024 · CellCentric Ltd.
2026-08 – 2031-11 · Multiple Myeloma Refractory, Multiple Myeloma in Relapse
What this study did
NCT05572515 · Janssen Research & Development, LLC
2023-03-29 – 2031-08-31 · Multiple Myeloma
What this study did
NCT07543458 · Oxford University Clinical Research Unit, Vietnam
2026-10-01 – 2031-07-31 · Dengue, Severe Dengue, Mosquito-Borne Diseases, Vector Borne Diseases, Arbovirus Infections, Flavivirus Infections, RNA Virus Infections, Hemorrhagic Fever
What this study did
NCT05561387 · SWOG Cancer Research Network
2023-10-12 – 2031-05-30 · Plasma Cell Myeloma
What this study did
NCT03742297 · PETHEMA Foundation
2018-10-22 – 2031-01 · Newly Diagnosed Multiple Myeloma
What this study did
NCT07828054 · Mario Negri Institute for Pharmacological Research
2026-12-20 – 2030-12-20 · Breast Cancer, Interstitial Lung Disease (ILD)
What this study did
NCT06136650 · Merck Sharp & Dohme LLC
2023-12-18 – 2030-12-02 · Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
What this study did
NCT06022939 · SWOG Cancer Research Network
2024-07-01 – 2030-10-29 · AL Amyloidosis
What this study did
NCT07584525 · University Medical Centre Ljubljana
2024-05-03 – 2030-09-30 · Tick-Borne Encephalitis
What this study did
NCT07576660 · Southeast University, China
2026-08-27 – 2030-09-30 · Acute Respiratory Distress Syndrome (ARDS)
What this study did
NCT04043494 · University Hospital Muenster
2019-08-23 – 2030-04-22 · Lymphoblastic Lymphoma, Childhood
What this study did
NCT06136624 · Merck Sharp & Dohme LLC
2023-12-31 – 2030-03-29 · Prostate Cancer Metastatic
What this study did
NCT03937635 · ECOG-ACRIN Cancer Research Group
2019-09-16 – 2029-12-31 · Smoldering Plasma Cell Myeloma
What this study did
NCT03710603 · Stichting European Myeloma Network
2018-12-14 – 2029-11 · Multiple Myeloma
What this study did
NCT07861776 · Post Graduate Institute of Medical Education and Research, Chandigarh
2026-10-15 – 2029-09-30 · Hemophagocytic Lymphohistiocytosis (HLH), Secondary Hemophagocytic Lymphohistiocytosis
What this study did
NCT03948035 · Wuerzburg University Hospital
2018-08-28 – 2029-08 · Newly Diagnosed Multiple Myeloma
What this study did
NCT05552976 · Bristol-Myers Squibb
2023-01-10 – 2029-07-25 · Relapsed or Refractory Multiple Myeloma
What this study did
NCT02339740 · Children's Oncology Group
2015-07-21 – 2029-06-30 · Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
What this study did
NCT04474223 · NYU Langone Health
2020-08-01 – 2029-06-30 · AVB - Atrioventricular Block, Fetal AVB
What this study did
NCT04484623 · GlaxoSmithKline
2020-10-01 – 2029-06-25 · Multiple Myeloma
What this study did
Phase 2/3 (70)
Other / comorbidity
NCT07887984 · Alliance for Clinical Trials in Oncology
2026-12-23 – 2053-08-01 · Multiple Myeloma (MM)
What this study did
NCT07072585 · Children's Oncology Group
2026-08-28 – 2035-09-01 · Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma, Stage IV T Lymphoblastic Leukemia/Lymphoma, T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
What this study did
NCT07570173 · Merck Sharp & Dohme LLC
2026-05-18 – 2033-10-18 · B-cell Acute Lymphoblastic Leukemia
What this study did
NCT05991388 · University of Birmingham
2024-05-02 – 2033-05-01 · B-cell Non Hodgkin Lymphoma
What this study did
NCT04513639 · Oslo University Hospital
2020-08-27 – 2032-06-01 · Multiple Myeloma
What this study did
NCT07185373 · Huashan Hospital
2025-10-01 – 2029-07-30 · Primary Central Nervous System Lymphoma
What this study did
NCT06879379 · Peking University People's Hospital
2025-03 – 2029-03 · Multiple Myeloma, Newly Diagnosed
What this study did
NCT06616584 · SWOG Cancer Research Network
2025-05-22 – 2028-12-31 · Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
NCT05665140 · University Hopsital Schleswig Holstein Campus Lübeck
2023-02-03 – 2028-10 · Newly Diagnosed Multiple Myeloma
What this study did
NCT03117751 · St. Jude Children's Research Hospital
2017-03-29 – 2028-09-30 · Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma
What this study did
NCT07827157 · Assiut University
2026-10 – 2027-11 · Rib Fractures, Acute Pain, Thoracic Trauma
What this study did
NCT06212336 · Irrua Specialist Teaching Hospital
2025-05-02 – 2027-06 · Lassa Fever
What this study did
NCT06913374 · Shandong University
2025-05-01 – 2027-05-30 · Thrombocytopenia
What this study did
NCT07853664 · Thamar University
2026-01-01 – 2027-01-01 · Facial Injuries, Pain, Swelling
What this study did
NCT02491632 · M.D. Anderson Cancer Center
2015-08-13 – 2026-12-31 · Advanced Malignant Neoplasm, Fatigue, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm, Refractory Malignant Neoplasm
What this study did
NCT04442022 · Karyopharm Therapeutics Inc
2020-09-03 – 2026-12 · Relapsed/Refractory Diffuse Large B-cell Lymphoma
What this study did
NCT07213375 · Copenhagen University Hospital, Rigshospitalet
2025-09-01 – 2026-11 · Analgetic, Lung Cancer (NSCLC), Video Assisted Thoracic Surgery (VATS), Glucocorticoid
What this study did
NCT05066997 · Oculis
2021-10-19 – 2026-04-10 · Diabetic Macular Edema
What this study did
NCT07290595 · Sahiwal medical college sahiwal
2025-01-13 – 2026-03-12 · Post Operative Analgesia, Bradycardia, Hypotension, Upper Limb Surgeries
What this study did
NCT07368075 · Sahiwal medical college sahiwal
2024-07-22 – 2026-01-15 · Post Operative Analgesia, Opioid Sparing Anaesthesia, Hypotension, Controlled, Bradycardia, Stoma Reversal Procedure
What this study did
NCT07343128 · Sanliurfa Education and Research Hospital
2025-06-01 – 2025-12-25 · Fibromyalgia
What this study did
NCT05809011 · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
2023-04-24 – 2025-12 · Acute Heart Failure
What this study did
NCT06166108 · Assiut University
2023-12 – 2025-11 · TAP Block
What this study did
NCT03759093 · National University Hospital, Singapore
2023-09-10 – 2025-09-10 · Multiple Myeloma
What this study did
NCT06496997 · Fayoum University
2024-08-01 – 2025-08-01 · Acute Respiratory Distress Syndrome
What this study did
NCT05546359 · Acacia Pharma Ltd
2024-01-18 – 2025-06-03 · Nausea and Vomiting, Postoperative
What this study did
NCT01228331 · Universitätsklinikum Hamburg-Eppendorf
2010-10 – 2024-11-20 · Leukemia
What this study did
NCT06266481 · Pharos University in Alexandria
2024-03-01 – 2024-05-30 · Postoperative Sore Throat
What this study did
NCT03874936 · Odense University Hospital
2020-11-12 – 2023-12-31 · Dexamethasone, Hip Dysplasia, Postoperative Pain, Postoperative Nausea and Vomiting
What this study did
NCT04452565 · Biomed Industries, Inc.
2022-06-15 – 2023-12-15 · Coronavirus Infection, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome Coronavirus 2
What this study did
NCT03692754 · Shandong University
2021-11-01 – 2023-12-01 · Immune Thrombocytopenia, Purpura, Thrombocytopenic
What this study did
NCT05998317 · Mansoura University
2023-10-08 – 2023-11-20 · Postoperative Nausea and Vomiting, Postoperative Pain, Laparoscopic Cholecystectomy
What this study did
NCT05553496 · Ain Shams University
2022-09-25 – 2023-10-01 · Pharmacological Action
What this study did
NCT05752305 · Universidad de Granada
2022-01-15 – 2023-07-15 · Inflammation, Pain, Postoperative, Trismus
What this study did
NCT03668639 · Christina Ruhlmann
2018-09-05 – 2023-04-15 · Chemotherapy-induced Nausea and Vomiting, Adverse Event, Cervical Cancer
What this study did
NCT00630565 · Masonic Cancer Center, University of Minnesota
2006-07-26 – 2022-07-28 · Leukemia
What this study did
NCT04027322 · Oman Medical Speciality Board
2019-06-01 – 2022-05-30 · Acute Pharyngitis
What this study did
NCT05145543 · Assiut University
2021-12-01 – 2022-03 · Endoscopic Sinus Surgery, Fentanyl
What this study did
NCT02938468 · University of Calgary
2016-09-17 – 2021-09 · Chronic Subdural Hematoma
What this study did
NCT03564704 · Nanfang Hospital, Southern Medical University
2016-02-14 – 2021-05-30 · Leukemia, Leukemia, Acute, Adult Lymphoblastic Lymphoma, Leukemia, Lymphoblastic, Leukemia, T Cell, Adult Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Lymphoblastic Leukemia
What this study did
NCT03098420 · University of Alabama at Birmingham
2016-07 – 2021-05-20 · Post Surgical Pain
What this study did
NCT03553238 · Nanfang Hospital, Southern Medical University
2016-02-14 – 2020-08-30 · Leukemia, Acute, Leukemia, T Cell, Leukemia, Lymphoblastic
What this study did
NCT00720109 · National Cancer Institute (NCI)
2008-07-14 – 2020-03-31 · Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
What this study did
NCT03863977 · Assiut University
2019-03-15 – 2020-01-01 · Postoperative Analgesia
What this study did
NCT02945527 · Universidad Peruana Cayetano Heredia
2015-12-04 – 2018-12 · Neurocysticercosis
What this study did
NCT02760043 · University Health Network, Toronto
2016-04 – 2018-10 · Total Knee Arthroplasty, Total Hip Arthroplasty, Osteoarthritis
What this study did
NCT03021772 · Assiut University
2017-01 – 2018-09-30 · Adjuvants, Anesthesia
What this study did
NCT02991339 · Shanghai Zhongshan Hospital
2016-06 – 2018-07 · Liver Dysfunction, Hepatectomy, Bilirubinaemia, Jaundice
What this study did
NCT03531970 · Isfahan University of Medical Sciences
2016-08-01 – 2017-12-01 · Local Anesthesia
What this study did
Phase 2 (884)
Ulcerative Colitis
NCT03456752 · Jinling Hospital, China
2018-06-01 – 2020-01-13 · Inflammatory Bowel Diseases, Dexamethasone, Postoperative Ileus, Postoperative Complications
What this study did
NCT01171807 · Quince Therapeutics S.p.A.
2003-07-22 – 2007-05-15 · Ulcerative Colitis
What this study did
Other / comorbidity
NCT07768943 · Fudan University
2026-09-01 – 2036-06-30 · Natural Killer/T-cell Lymphoma
What this study did
NCT07247097 · Massachusetts General Hospital
2026-08-01 – 2035-12-01 · Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant Ineligible, Newly Diagnosed Multiple Myeloma (NDMM)
What this study did
NCT07227584 · Dana-Farber Cancer Institute
2026-04-03 – 2035-07-31 · Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL), Leukemia
What this study did
NCT07856069 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2026-10 – 2034-10 · Medulloblastoma
What this study did
NCT06533748 · St. Jude Children's Research Hospital
2025-01-23 – 2034-05 · Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
What this study did
NCT02106988 · M.D. Anderson Cancer Center
2015-01-16 – 2034-01-31 · Lymphoma
What this study did
NCT06099366 · Hee Young Ju
2024-03-05 – 2033-12-31 · Lymphoblastic Leukemia in Children
What this study did
NCT06390319 · St. Jude Children's Research Hospital
2024-12-27 – 2033-12 · T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, Mixed Phenotype Acute Leukemia
What this study did
NCT07709000 · Merck Sharp & Dohme LLC
2026-10-14 – 2033-11-16 · Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Hematologic Malignancies
What this study did
NCT03418038 · Mayo Clinic
2018-03-23 – 2033-11-02 · Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Lymphoma, Chronic Myelomonocytic Leukemia
What this study did
NCT07914309 · Washington University School of Medicine
2026-11-30 – 2033-05-31 · Triple Negative Breast Cancer, Triple Negative Breast Cancer (TNBC), Breast Cancer
What this study did
NCT05145400 · UNC Lineberger Comprehensive Cancer Center
2022-02-18 – 2033-05-28 · Multiple Myeloma, Cancer
What this study did
NCT07748689 · Polish Myeloma Consortium
2026-10 – 2033-03 · Relapsed / Refractory Multiple Myeloma
What this study did
NCT05986318 · David Palma
2025-01-07 – 2032-12-31 · Lung Cancer, Interstitial Lung Disease
What this study did
NCT07901868 · PETHEMA Foundation
2026-11-01 – 2032-12 · Multiple Myeloma Refractory, Multiple Myeloma in Relapse
What this study did
NCT07605416 · National Cancer Institute (NCI)
2027-04-20 – 2032-11-06 · Plasma Cell Leukemia
What this study did
NCT06762769 · University College, London
2025-06-02 – 2032-11-01 · Smouldering Myeloma
What this study did
NCT04933539 · National Cancer Institute (NCI)
2022-10-31 – 2032-10-31 · Multiple Myeloma
What this study did
NCT07636564 · SWOG Cancer Research Network
2026-10-14 – 2032-04-16 · Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia
What this study did
NCT06616597 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2025-02-13 – 2032-03-30 · Prostate Cancer (Adenocarcinoma), Metastatic Prostate Cancer
What this study did
NCT06788912 · Merck Sharp & Dohme LLC
2025-03-20 – 2032-02-06 · Lung Neoplasm Malignant
What this study did
NCT04883242 · University of Washington
2021-07-29 – 2031-12-31 · Recurrent Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT03289299 · International Myeloma Foundation
2018-05-25 – 2031-11-15 · Smoldering Multiple Myeloma
What this study did
NCT07785609 · Merck Sharp & Dohme LLC
2026-10-07 – 2031-09-30 · Advanced Solid Tumors, Malignant Neoplasm
What this study did
NCT05896228 · Benjamin T Diamond, MD
2024-02-20 – 2031-03-01 · Refractory Multiple Myeloma, Relapsed Multiple Myeloma
What this study did
NCT05272826 · Canadian Myeloma Research Group
2024-12-12 – 2031-03 · Multiple Myeloma
What this study did
NCT07614360 · GlaxoSmithKline
2026-08-03 – 2031-02-11 · Multiple Myeloma
What this study did
NCT07825064 · Hoffmann-La Roche
2026-11-03 – 2031-01-19 · Multiple Myeloma
What this study did
NCT05922501 · Massachusetts General Hospital
2024-05-31 – 2030-12-31 · Relapsed Cancer, Refractory Multiple Myeloma, Multiple Myeloma
What this study did
DARA RVD For High Risk SMMactive not recruiting
NCT04775550 · Omar Nadeem, MD
2021-03-08 – 2030-12-08 · High-risk Smoldering Multiple Myeloma, Multiple Myeloma
What this study did
NCT04240054 · Medical College of Wisconsin
2021-11-02 – 2030-12-01 · Multiple Myeloma
What this study did
NCT07803562 · University of California, San Diego
2026-11 – 2030-12 · Uveal Melanoma, Metastatic
What this study did
NCT05977998 · M.D. Anderson Cancer Center
2023-09-08 – 2030-10-31 · Gastric Adenocarcinoma, Carcinomatosis
What this study did
NCT06997081 · University of Miami
2025-09-16 – 2030-09-30 · Multiple Myeloma
What this study did
NCT07159620 · The First Affiliated Hospital of Soochow University
2025-09-01 – 2030-09-01 · Adult T-cell Leukemia/Lymphoma
What this study did
NCT06905509 · University of California, Davis
2025-07-31 – 2030-08-01 · Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Nodal Marginal Zone Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
What this study did
NCT04488081 · QuantumLeap Healthcare Collaborative
2020-07-31 – 2030-07-31 · COVID-19
What this study did
NCT07002216 · University of Miami
2025-07-15 – 2030-07-15 · Hodgkin Lymphoma, Advanced Hodgkin Lymphoma
What this study did
NCT06353022 · Nantes University Hospital
2024-06-26 – 2030-06-26 · Multiple Myeloma
What this study did
NCT07560449 · Qilu Pharmaceutical Co., Ltd.
2026-06 – 2030-06 · Malignant Plasma Cell Neoplasms
What this study did
NCT07643103 · Institute of Hematology & Blood Diseases Hospital, China
2026-06-12 – 2030-05-31 · Ph- Acute Lymphoblastic Leukemia (Ph-ALL)
What this study did
NCT06627751 · Roswell Park Cancer Institute
2025-05-01 – 2030-05-01 · Extramedullary Disease in Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT05530421 · University of Miami
2023-03-26 – 2030-03-26 · Relapsed and Refractory Multiple Myeloma
What this study did
Phase 1/2 (241)
Crohn's Disease
NCT05432934 · University of Saskatchewan
2022-09-01 – 2024-08-31 · Colorectal Disorders, Regional Anesthesia Morbidity, Analgesia, Local Anesthetic Complication, Pain, Postoperative, Colorectal Cancer, Crohn Disease, Diverticular Diseases
What this study did
Other / comorbidity
NCT07600151 · Universitätsklinikum Hamburg-Eppendorf
2026-12-01 – 2036-12-31 · Myeloma Multiple, Myeloma
What this study did
NCT07387926 · Novartis Pharmaceuticals
2026-07-05 – 2036-05-30 · Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
What this study did
NCT05848687 · Tanja Andrea Gruber
2023-11-03 – 2033-12 · Lymphoblastic Leukemia
What this study did
NCT04822337 · Wake Forest University Health Sciences
2021-05-19 – 2032-11 · Multiple Myeloma
What this study did
NCT07175415 · Princess Maxima Center for Pediatric Oncology
2026-10-01 – 2032-10-01 · Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
What this study did
NCT07908524 · Merck Sharp & Dohme LLC
2026-12-14 – 2032-06-29 · Metastatic Castration-resistant Prostate Cancer
What this study did
NCT05745714 · Princess Maxima Center for Pediatric Oncology
2025-10-01 – 2032-02-02 · Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
What this study did
NCT05751044 · Princess Maxima Center for Pediatric Oncology
2025-10-01 – 2032-02-01 · Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
What this study did
NCT02553460 · St. Jude Children's Research Hospital
2016-01-29 – 2031-10 · Acute Lymphoblastic Leukemia
What this study did
NCT07770698 · BeOne Medicines
2026-12 – 2031-09 · Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, Pediatric Cancer, Pediatric ALL, Relapsed, Pediatric ALL, Pediatric ALL, B Cell, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Pediatric AML, R/R AML, R/R B-cell ALL
What this study did
NCT07876128 · Merck Sharp & Dohme LLC
2026-11-16 – 2031-05-30 · Advanced Solid Tumors, Malignant Neoplasm
What this study did
NCT06785415 · Mayo Clinic
2025-03-18 – 2031-04-01 · Recurrent Multiple Myeloma
What this study did
NCT02813135 · Gustave Roussy, Cancer Campus, Grand Paris
2016-08-03 – 2031-02 · Pediatric Cancer
What this study did
NCT06232044 · Alliance for Clinical Trials in Oncology
2025-04-23 – 2030-08-01 · Recurrent Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT07870447 · NYU Langone Health
2026-11-01 – 2029-12-30 · Adenotonsillectomy, Postoperative Pain
What this study did
NCT07479979 · Natalie Callander
2026-05-21 – 2029-07 · Relapse Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT05658640 · Princess Maxima Center for Pediatric Oncology
2023-11-14 – 2029-04-01 · Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
What this study did
NCT06383572 · M.D. Anderson Cancer Center
2024-06-26 – 2029-04-01 · Lymphodepleting Chemotherapy, Myeloid Malignancies
What this study did
NCT07832110 · The University of Texas Health Science Center at San Antonio
2026-10 – 2029-03 · Post Operative Pain, Acute, Periodontitis
What this study did
NCT06353386 · Merck Sharp & Dohme LLC
2024-05-20 – 2029-01-15 · Prostatic Neoplasms, Castration-Resistant
What this study did
NCT05486481 · Alfred Chung, MD
2024-01-08 – 2028-12-31 · AL Amyloidosis, Light Chain (AL) Amyloidosis, Systemic Light Chain Disease
What this study did
NCT05392946 · Mayo Clinic
2022-08-11 – 2028-09-29 · Plasma Cell Myeloma
What this study did
NCT05714839 · GlaxoSmithKline
2023-06-14 – 2028-08-03 · Multiple Myeloma
What this study did
NCT05434689 · University of Alabama at Birmingham
2023-01-18 – 2028-08 · Multiple Myeloma
What this study did
NCT05583617 · Hoffmann-La Roche
2023-11-14 – 2028-07-31 · Multiple Myeloma
What this study did
NCT02773030 · Celgene
2016-10-14 – 2028-07-28 · Multiple Myeloma
What this study did
NCT02861573 · Merck Sharp & Dohme LLC
2016-11-17 – 2028-07-24 · Metastatic Castration-Resistant Prostate Cancer
What this study did
NCT05060627 · PETHEMA Foundation
2021-12-20 – 2028-05-30 · Relapsed Multiple Myeloma
What this study did
NCT04643002 · Sanofi
2021-01-25 – 2028-04-20 · Plasma Cell Myeloma Refractory
What this study did
NCT07210047 · HuniLife Biotechnology, Inc.
2025-08-18 – 2028-01-31 · Multiple Myeloma Refractory
What this study did
NCT06106945 · AstraZeneca
2023-12-05 – 2028-01-24 · Multiple Myeloma
What this study did
NCT07504822 · Yohanes Firmansyah, dr, MH, MM
2026-04-18 – 2028-01-18 · Acne Vulgaris
What this study did
NCT06207305 · M.D. Anderson Cancer Center
2024-01-30 – 2028-01-02 · Metastatic Appendiceal Adenocarcinoma, Intraperitoneal Paclitaxel
What this study did
NCT06574048 · University of Nebraska
2026-10 – 2028-01 · Carbon Monoxide Poisoning, Carbon Monoxide Intoxication, Carbon Monoxide Encephalopathy, Carbon Monoxide-induced Parkinsonism
What this study did
NCT04225611 · Massachusetts Eye and Ear Infirmary
2021-03-15 – 2027-12-31 · Cystoid Macular Edema
What this study did
NCT03715478 · Canadian Myeloma Research Group
2018-11-26 – 2027-12-31 · Relapsed and/or Refractory Multiple Myeloma
What this study did
NCT01371630 · M.D. Anderson Cancer Center
2011-08-26 – 2027-12-25 · B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Burkitt-Like Lymphoma With 11q Aberration, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Burkitt Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory Burkitt Lymphoma
What this study did
NCT04764942 · Mayo Clinic
2021-05-06 – 2027-12-17 · Recurrent Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT04947189 · St Vincent's Hospital, Sydney
2022-11-01 – 2027-12-01 · Triple Negative Breast Cancer
What this study did
NCT06376721 · Beijing Tongren Hospital
2024-04-14 – 2027-10-31 · Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, T-lymphoblastic Lymphoma
What this study did
NCT06645678 · YOUNGIL KOH
2024-11-26 – 2027-10-01 · Relapsed Refractory Multiple Myeloma (RRMM)
What this study did
NCT05451771 · Columbia University
2022-10-26 – 2027-09 · AL Amyloidosis
What this study did
NCT05514990 · University of Southern California
2022-10-07 – 2027-08-22 · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
Phase 1 (347)
Other / comorbidity
NCT06518551 · Omar Nadeem, MD
2024-11-01 – 2034-12-31 · Myeloma, Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT07513129 · M.D. Anderson Cancer Center
2026-06-05 – 2031-12-31 · T-cell Acute Lymphoblastic Leukemia, Lymphoma
What this study did
NCT07609706 · GlaxoSmithKline
2026-10-23 – 2031-08-22 · Multiple Myeloma
What this study did
NCT07870278 · Merck Sharp & Dohme LLC
2026-11-13 – 2031-07-07 · Ovarian Neoplasms, Endometrial Neoplasms
What this study did
NCT05292664 · Andrew E. Place, MD
2023-03-29 – 2030-07-02 · Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated, Treatment-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Lymphoblastic Lymphoma, in Relapse, Lymphoblastic Lymphoma, Refractory, Acute Leukemia of Ambiguous Lineage in Relapse, Acute Leukemia of Ambiguous Lineage
What this study did
NCT06622005 · Roswell Park Cancer Institute
2025-04-10 – 2030-04-10 · Recurrent Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT07072234 · M.D. Anderson Cancer Center
2025-09-25 – 2030-02-01 · Clear Cell Carcinoma, Phase 1, Growth Factor
What this study did
NCT05521087 · Janssen Research & Development, LLC
2025-12-26 – 2030-01-29 · Acute Leukemias, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Leukemia of Ambiguous Lineage
What this study did
NCT07608731 · Allison Winter
2026-10 – 2029-09 · Large B-cell Lymphoma, Central Nervous System Lymphoma
What this study did
NCT06348108 · Alfred Chung, MD
2025-07-28 – 2029-07-31 · Multiple Myeloma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
What this study did
NCT06190158 · Brigham and Women's Hospital
2024-05-15 – 2029-07-31 · Type 2 Diabetes, Chronic Kidney Diseases
What this study did
NCT03805932 · National Cancer Institute (NCI)
2019-10-03 – 2029-06-30 · Hairy Cell Leukemia
What this study did
NCT04729114 · Astellas Pharma Global Development, Inc.
2021-06-14 – 2029-05-31 · Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
What this study did
NCT07341867 · Andrew Hantel, MD
2026-07-30 – 2029-03-31 · Multiple Myeloma, Triple Negative Breast Cancer, Duffy Blood Group, Chemokine Receptor Gene Mutation, Duffy Blood Group, Chemokine Receptor Gene C.-67T>C
What this study did
NCT06863259 · Children's Hospital Medical Center, Cincinnati
2025-05-21 – 2029-01-01 · B-cell Acute Lymphoblastic Leukemia
What this study did
NCT03719105 · New York Medical College
2019-03-01 – 2028-12-31 · NK-Cell Lymphoma, NK-Cell Leukemia, Peripheral T Cell Lymphoma
What this study did
NCT04910568 · Genentech, Inc.
2021-07-26 – 2028-12-21 · Multiple Myeloma
What this study did
NCT07791264 · City of Hope Medical Center
2027-02-17 – 2028-08-28 · Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Malignant Glioma
What this study did
NCT06121843 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
2024-02-22 – 2028-08-01 · Multiple Myeloma
What this study did
NCT07662200 · Ottawa Hospital Research Institute
2026-08 – 2028-08 · Germ Cell Cancer
What this study did
NCT04754945 · Emory University
2021-04-28 – 2028-07-24 · AL Amyloidosis
What this study did
NCT07032714 · Massachusetts General Hospital
2025-12-19 – 2028-07-01 · Relapsed Refractory Multiple Myeloma (RRMM)
What this study did
NCT07891039 · Carilion Clinic
2026-10-01 – 2028-06-30 · Breast Reconstruction, Free Flap Reconstruction
What this study did
NCT04847453 · National Cancer Institute (NCI)
2022-08-03 – 2028-06-30 · Recurrent AL Amyloidosis, Refractory AL Amyloidosis
What this study did
NCT07343817 · Ahmed Nassar Ibrahim Mohammed
2026-07-01 – 2028-04-01 · Trauma Injury
What this study did
NCT04091126 · GlaxoSmithKline
2019-12-18 – 2028-03-10 · Multiple Myeloma
What this study did
NCT07082270 · Roswell Park Cancer Institute
2026-04-01 – 2028-02-01 · Recurrent Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT06016465 · Texas Tech University Health Sciences Center, El Paso
2023-09-15 – 2028-01-30 · Migraine
What this study did
NCT03132454 · M.D. Anderson Cancer Center
2017-07-25 – 2027-12-31 · Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT05495035 · Institute of Hematology & Blood Diseases Hospital, China
2022-09-01 – 2027-12-01 · Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Relapsed Leukemia, Refractory Leukemia
What this study did
NCT01562405 · Massachusetts General Hospital
2012-05 – 2027-12 · Multiple Myeloma
What this study did
NCT07224334 · David D'Alessio, M.D.
2025-12-30 – 2027-12 · Diabetes (DM)
What this study did
NCT06433947 · Opna Bio LLC
2024-08-22 – 2027-12 · Relapsed Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT05476770 · Therapeutic Advances in Childhood Leukemia Consortium
2022-11-11 – 2027-11-11 · Hematologic Malignancy, AML, ALL, BPDCN, MDS, Lymphoblastic Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia
What this study did
NCT03571321 · University of Chicago
2019-05-28 – 2027-09-05 · Acute Lymphoblastic Leukemia, ALL, Childhood, ALL
What this study did
NCT06428630 · Tufts University
2025-05-01 – 2027-09-01 · Oral Lichen Planus, Oral Lichenoid Reaction
What this study did
NCT07444710 · National Cancer Institute (NCI)
2026-12-30 – 2027-09-01 · Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma, Ann Arbor Stage IV Mantle Cell Lymphoma
What this study did
NCT03909412 · Hackensack Meridian Health
2019-10-08 – 2027-08 · Multiple Myeloma
What this study did
NCT03798678 · National Cancer Institute (NCI)
2019-07-08 – 2027-07-16 · Recurrent Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT02494882 · Memorial Sloan Kettering Cancer Center
2015-06-29 – 2027-06 · Acute Lymphoblastic Leukemia
What this study did
NCT07812259 · Centre Hospitalier Universitaire de Nīmes
2026-05-18 – 2027-06 · Parotid Neoplasm, Bupivacaine, Dexamethasone
What this study did
NCT03740334 · Dana-Farber Cancer Institute
2019-01-30 – 2027-04-30 · Acute Lymphoblastic Leukemia ALL
What this study did
NCT07380139 · Ain Shams University
2026-02-01 – 2027-01-01 · Post Operative Pain
What this study did
NCT06429982 · Children's National Research Institute
2024-10-01 – 2026-12-31 · Rhabdomyolysis
What this study did
NCT04756726 · C4 Therapeutics, Inc.
2021-04-27 – 2026-12-31 · Multiple Myeloma, Lymphoma, Non-Hodgkin's
What this study did
NCT05981209 · Abdullah Khan
2023-12-21 – 2026-12-31 · Recurrent Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT04161248 · Canadian Cancer Trials Group
2020-09-02 – 2026-12-31 · Lymphoma, B-Cell
What this study did
Phase 4 (499)
Crohn's Disease
NCT03723447 · Cedars-Sinai Medical Center
2018-10-23 – 2019-10-29 · Pain, Postoperative, Crohn Disease, Inflammatory Bowel Diseases, Colorectal Cancer, Gastrointestinal Cancer, Gastrointestinal Disease, Digestive System Disease, Pain, Pain, Neuropathic, Intestinal Disease
What this study did
Other / comorbidity
NCT06289673 · St. Jude Children's Research Hospital
2024-12-26 – 2039-05 · Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia
What this study did
NCT04432012 · Christian Candrian
2020-07-01 – 2033-04-30 · Total Knee Replacement
What this study did
NCT04507412 · Christian Candrian
2020-09-09 – 2032-08-31 · Arthroplasty, Replacement, Shoulder
What this study did
NCT01553214 · National Institutes of Health Clinical Center (CC)
2012-12-31 – 2032-01-01 · Allogeneic Granulocyte Donation
What this study did
NCT07084441 · University of Washington
2026-02-03 – 2030-12 · Adhesive Small Bowel Obstruction
What this study did
NCT07762170 · Igor Wilderman. MD
2026-07-30 – 2030-03 · Back Pain Lower Back, Neck Pain, Radiculopathy Multiple Sites, Spinal Stenosis Cervicothoracic Region, Spinal Stenosis Lumbar, Failed Back Surgery Syndrome (FBSS), Sciatica, Intervertebral Disc Disorders With Radiculopathy, Lumbar Region, Spine Osteoarthritis
What this study did
NCT03829371 · University of Turin, Italy
2019-01-03 – 2030-01-03 · Multiple Myeloma
What this study did
NCT07777276 · Telethon Kids Institute
2026-08-17 – 2029-08-17 · Postoperative Sleep Quality, Postoperative Behaviour, Postoperative Recovery in Children, Postoperative Nausea and Vomiting (PONV), Paediatric Surgery, Anaesthesia
What this study did
NCT07843849 · Vanderbilt University Medical Center
2026-04-07 – 2029-03 · Diabetic Macular Edema (DME), Diabetic Retinopathy
What this study did
Prevent Wheeze Trialnot yet recruiting
NCT07858773 · Norwegian University of Science and Technology
2027-02-01 – 2029-01-30 · Lower Respiratory Tract Infection (LRTI), Recurrent Wheezing
What this study did
NCT03661645 · Emory University
2018-09-07 – 2029-01 · Orthopedic Surgeries
What this study did
NCT06023043 · Children's Hospital Los Angeles
2025-11-01 – 2028-12-31 · Neuromuscular Scoliosis, Adolescent Idiopathic Scoliosis
What this study did
NCT07709884 · The First Affiliated Hospital of Soochow University
2026-07-01 – 2028-12-31 · Newly Diagnosed Multiple Myeloma, T(11;14), Sotoclax, Carfilzomib
What this study did
NCT06878599 · Assiut University
2025-05-01 – 2028-10 · Sudden Sensorineural Hearing Loss (SSNHL)
What this study did
NCT06968507 · Dr. Lutfi Kirdar Kartal Training and Research Hospital
2024-12-25 – 2028-09-10 · Sudden Sensorineural Hearing Loss
What this study did
NCT07556952 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2026-04-13 – 2028-06-30 · Post-Mastectomy Chronic Pain Syndrome
What this study did
NCT04150614 · University of Illinois Chicago
2020-05-14 – 2028-03 · Nausea With Vomiting Chemotherapy-Induced
What this study did
NCT07890220 · Poznan University of Medical Sciences
2026-11-01 – 2028-01-01 · Adolescent Idiopathic Scoliosis (AIS)
What this study did
NCT07287826 · Woman's
2026-04-02 – 2028-01 · Oral Mucositis Due to Chemotherapy
What this study did
NCT06590402 · Hospital for Special Surgery, New York
2025-06-06 – 2028-01 · Anterior Cruciate Ligament Reconstruction, Medial Patellofemoral Ligament Reconstruction
What this study did
NCT06409702 · The First Affiliated Hospital of Soochow University
2024-06-12 – 2027-12-31 · Newly Diagnosed, High Risk, MRD, Multiple Myeloma
What this study did
NCT05793060 · Damanhour Teaching Hospital
2026-08-01 – 2027-12-15 · Analgesia
What this study did
Exparel and Dexamethasonenot yet recruiting
NCT07614802 · Duke University
2026-11-01 – 2027-12-01 · Postoperative Pain, Shoulder Arthroscopic Surgeries
What this study did
NCT06603662 · WellSpan Health
2025-02-24 – 2027-12 · Osteoarthritis, Osteoarthritis (OA) of the Knee, Osteoarthritis (OA) of the Shoulder, Osteoarthritis (OA) of the Hip
What this study did
NCT07605065 · Pak Emirates Military Hospital
2026-11-01 – 2027-11-01 · Primary Headache
What this study did
NCT05023369 · Ente Ospedaliero Cantonale, Bellinzona
2021-12-10 – 2027-11-01 · Femoral Neck Fractures
What this study did
NCT07793760 · Assiut University
2026-10 – 2027-11 · Preeclampsia, Spinal Anesthesia-Induced Hypotension, Cesarean Section
What this study did
NCT07360431 · Assiut University
2026-03 – 2027-10 · Postoperative Nausea and Vomiting (PONV)
What this study did
NCT05721027 · Montefiore Medical Center
2023-07-05 – 2027-10 · Radiculopathy, Lumbosacral Region, Back Pain With Radiation, Low Back Pain
What this study did
NCT06811675 · China Medical University Hospital
2025-03-23 – 2027-09-30 · Carbon Monoxide Poisoning, Delayed Neurocognitive Sequelae
What this study did
NCT07855341 · Ain Shams University
2026-10-15 – 2027-09-14 · Pain, Postoperative, Muscle Weakness, Arthroplasty, Replacement, Hip
What this study did
NCT07615595 · University Medical Center Ho Chi Minh City (UMC)
2025-08-01 – 2027-07-31 · Hypotension During Cesarean Delivery, Postoperative Nausea and Vomiting (PONV), Pain, Postoperative
What this study did
NCT07699744 · Seoul National University Hospital
2026-08-25 – 2027-07-15 · Pain, Postoperative, Rebound Pain, Shoulder Injuries, Rotator Cuff Injuries
What this study did
NCT05435547 · Indiana University
2023-06-16 – 2027-06-30 · Graves Disease, Hashimoto Disease
What this study did
NCT06268704 · University of New Mexico
2024-03-27 – 2027-05-01 · Sacroiliac Joint Dysfunction, Sacro-Iliac Spondylosis
What this study did
NCT07494136 · University of Miami
2026-09-15 – 2027-05 · Lumbar Radiculopathy, Sciatica, Back Pain With Radiation
What this study did
NCT07911202 · Sohag University
2026-11 – 2027-05 · Post Operative Pain, Emergence Agitation, Functional Endoscopic Sinus Surgery
What this study did
NCT07064993 · Arzu Esen Tekeli
2025-06-15 – 2027-04-30 · Knee Arthroscopy, Postoperative Pain
What this study did
NCT07378215 · Ziekenhuis Oost-Limburg
2026-01-30 – 2027-02 · Postoperative Quality of Recovery, Health-Related Quality-of-Life, Quality of Life
What this study did
NCT06692010 · Assiut University
2024-12-01 – 2027-01-01 · Clavicle Fracture
What this study did
NCT06704139 · Assiut University
2024-12-01 – 2027-01-01 · Cesarean Section
What this study did
NCT06715709 · Mayo Clinic
2025-03-25 – 2027-01-01 · Arthropathy of Knee
What this study did
NCT07795281 · Gaziantep City Hospital
2026-09 – 2027-01 · Postoperative Pain, Arthroscopic Shoulder Surgery, Regional Anesthesia
What this study did
NCT07482891 · Shanghai 6th People's Hospital
2026-03-10 – 2026-12-31 · Chemotherapy-induced Nausea and Vomiting
What this study did
NCT07819682 · Holy Family Hospital, Pakistan
2026-08-15 – 2026-12-15 · Dexamethasone, Spinal Anesthesia, Adjuvant
What this study did
NCT04182997 · University of Missouri-Columbia
2019-11-21 – 2026-12 · Lumbar Disc Herniation
What this study did
Early phase / not applicable (442)
Crohn's Disease
NCT02402543 · University of Vermont
2014-06 – 2017-05 · Hemorrhoids, Fissure in Ano, Rectal Fistula, Anal Condyloma
What this study did
Ulcerative Colitis
NCT00152620 · University of Chicago
2004-06 – 2007-05 · Inflammatory Bowel Disease (IBD)
What this study did
Other / comorbidity
NCT04209218 · Peking University First Hospital
2020-04-07 – 2029-12 · Lung Cancer, Surgery, Blood Pressure Management, Dexamethasone, Overall Survival, Postoperative Complications
What this study did
NCT07299435 · University Hospital Ostrava
2026-01-05 – 2029-01 · Tonsil Hypertrophy
What this study did
NCT06984822 · Vastra Gotaland Region
2025-08-01 – 2028-12-31 · Diabetic Macular Edema, Visual Impairment, Diabetes Mellitus, Hyperglycaemia (Diabetic), Oxidative Stress, Vascular Endothelial Growth Factor, VEGF
What this study did
NCT07344246 · Beijing Tiantan Hospital
2026-09-01 – 2028-12-01 · Herpes Zoster Pain
What this study did
NCT07923643 · Assiut University
2026-11-01 – 2028-11 · Breast Cancer, Postoperative Pain, Chronic Postoperative Pain, Quality of Recovery
What this study did
NCT05889221 · Poitiers University Hospital
2023-10-23 – 2028-09-01 · Multiple Myeloma, Myeloma Multiple, Myeloma
What this study did
NCT07442890 · Henan Cancer Hospital
2026-04-30 – 2028-06-30 · Lung Cancer
What this study did
NCT05024344 · University of Tennessee Medical Center
2021-08-09 – 2028-06-30 · Nephrolithotomy, Percutaneous
What this study did
NCT07877519 · China National Center for Cardiovascular Diseases
2026-06-01 – 2028-06 · Paroxysmal Atrial Fibrillation
What this study did
NCT04266977 · Insel Gruppe AG, University Hospital Bern
2020-05-08 – 2028-04 · Glioblastoma, Dexamethasone, Steroids
What this study did
NCT05635227 · Copenhagen University Hospital, Rigshospitalet
2022-11-10 – 2028-02 · Coronary Artery Disease, Aortic Valve Disease
What this study did
NCT07345819 · The Hospital for Sick Children
2026-04-01 – 2027-12-31 · Orbital Cellulitis
What this study did
NCT05631405 · Chulalongkorn University
2022-10-16 – 2027-12-31 · Severe Dengue
What this study did
NCT07341854 · Beijing Tiantan Hospital
2026-04-06 – 2027-12-30 · Pain, Postoperative, Dexamethasone Palmitate
What this study did
NCT07324499 · Pontificia Universidad Catolica de Chile
2026-05-19 – 2027-12-01 · Pain, Interscalene Blocks, Dexamethasone, Bupivacaine
What this study did
NCT06080880 · Hubei Cancer Hospital
2023-12-01 – 2027-11 · Nausea With Vomiting Chemotherapy-Induced
What this study did
NCT07837674 · Centre hospitalier de l'Université de Montréal (CHUM)
2026-11 – 2027-11 · Spinal Anesthesia, Prolonged Sensory Block, Prolonged Motor Block
What this study did
NCT07677215 · Poznan University of Medical Sciences
2026-05-20 – 2027-10-01 · Knee Osteoarthritis
What this study did
NCT07044557 · University of Louisville
2026-08-01 – 2027-10 · Brain Metastases
What this study did
NCT07568184 · Kafrelsheikh University
2026-04-03 – 2027-08 · Sensori-Neural Deafness, Exosomes
What this study did
NCT07581470 · Poznan University of Medical Sciences
2026-05-08 – 2027-07-31 · Osteoarthritis, Hip, Hip Osteoarthritis
What this study did
NCT07607691 · Ankara City Hospital Bilkent
2026-06-01 – 2027-07-15 · Chronic Shoulder Pain, Pericapsular Nerve Group Block (PENG Block), Frozen Shoulder, Bursitis, Rotator Cuff Disorders
What this study did
NCT07550803 · Seoul National University Hospital
2026-06-01 – 2027-07-01 · Sleep Disturbance
What this study did
NCT06924424 · Peking University People's Hospital
2025-03-01 – 2027-06-30 · Multiple Myeloma, Neoplasms
What this study did
NCT06988124 · Beijing Tiantan Hospital
2025-06-25 – 2027-06-01 · Postoperative Nausea and Vomiting
What this study did
NCT07760272 · B.P. Koirala Institute of Health Sciences
2027-01 – 2027-06 · Postoperative Sore Throat, Cough, Hoarseness
What this study did
NCT05936086 · shifeng Lou
2023-04-20 – 2027-05-20 · Hemophagocytic Syndrome
What this study did
NCT07584200 · Poznan University of Medical Sciences
2026-05-07 – 2027-05-01 · Arthropathy of Hip, Hip Osteoarthritis
What this study did
NCT07073209 · Weill Medical College of Cornell University
2025-07-10 – 2027-04 · Hip Fractures
What this study did
NCT06192979 · Jin Lu, MD
2024-01-05 – 2027-03-31 · Amyloidosis; Systemic, AL Amyloidosis
What this study did
NCT07722091 · Fujian Medical University Union Hospital
2026-07-27 – 2027-03-01 · Hoarseness, Post Operative Complicaiton
What this study did
NCT06999070 · Assiut University
2025-05 – 2027-03 · Post Spinal Anesthesia Shivering
What this study did
NCT07655908 · Universidad Simón Bolívar
2026-06-15 – 2027-02 · Pain, Acute Post-Operative, Nausea and Vomiting, Postoperative
What this study did
NCT07289620 · Poznan University of Medical Sciences
2026-01-16 – 2027-01-31 · Ankle Disease, Foot Diseases
What this study did
NCT07474909 · Poznan University of Medical Sciences
2025-12-10 – 2027-01-31 · Hand Injuries and Disorders, Wrist Sprain
What this study did
NCT07327931 · Poznan University of Medical Sciences
2026-02-13 – 2027-01-31 · Hip Osteoarthritis, Hip Pain Chronic
What this study did
NCT06846073 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2024-07-30 – 2026-12-31 · Diabetic Macular Edema (DME)
What this study did
NCT06997419 · Beijing Tiantan Hospital
2025-07-01 – 2026-12-31 · Postoperative Nausea and Vomiting, Dexamethasone Palmitate, Open Surgery
What this study did
NCT06410443 · General Hospital of Shenyang Military Region
2024-08-01 – 2026-12-31 · Radiation-Induced Intestinal Injury
What this study did
NCT07077850 · Al-Quds University
2025-08-20 – 2026-12-20 · Post Operative Urinary Retention, Spinal Aneshtesia
What this study did
NCT07672873 · Marmara University
2026-06-15 – 2026-12-18 · Symptomatic Irreversible Pulpitis (SIP), Dental Pain
What this study did
NCT06793475 · Institute of Hematology & Blood Diseases Hospital, China
2025-04-09 – 2026-12 · Extramedullary Multiple Myeloma
What this study did
NCT07609836 · Ain Shams University
2026-05 – 2026-12 · We Are Studying the Effects of Caudal Dexamethasone in Neonates Undergoing Inguinal Hernia Repair
What this study did
NCT07631910 · Sir Run Run Shaw Hospital
2026-07-01 – 2026-10-31 · Nausea and Vomiting, Postoperative
What this study did
NCT07386600 · Poznan University of Medical Sciences
2026-02-05 – 2026-10-02 · Knee Osteoarthritis
What this study did
NCT06946069 · Assiut University
2025-09-01 – 2026-09-30 · Vitiligo, NB-UVB
What this study did
NCT07015021 · The First Affiliated Hospital of Soochow University
2025-06-01 – 2026-09-30 · Multiple Myeloma, Carfilzomib, Daratumumab, Pomalidomide
What this study did
NCT07821359 · CMH Lahore Medical College and Institute of Dentistry
2026-02-28 – 2026-09-30 · Symptomatic Irreversible Pulpitis
What this study did
Used as active comparator (164)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (69)
Other / comorbidity
NCT07649525 · University of Leeds
2026-07-03 – 2037-06 · Multiple Myeloma (MM), Plasma Cell Leukemia (PCL)
What this study did
NCT07901725 · Regeneron Pharmaceuticals
2026-12-18 – 2035-07-25 · Newly Diagnosed Amyloidosis, Amyloidosis Stage I-IIIA
What this study did
NCT07766421 · Cellectar Biosciences, Inc.
2026-12 – 2035-01 · Waldenstrom Macroglobulinaemia, Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinaemia Refractory, Waldenstrom Macroglobulinemia With Nodal Disease, Waldenstrom's Macroglobulinemia Recurrent
What this study did
NCT05730036 · Regeneron Pharmaceuticals
2023-09-18 – 2033-04-19 · Relapsed Refractory Multiple Myeloma (RRMM)
What this study did
NCT06413498 · Kite, A Gilead Company
2024-08-23 – 2031-07 · Multiple Myeloma
What this study did
NCT07569757 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2026-06 – 2030-12 · Multiple Myeloma
What this study did
NCT06464991 · Nanjing IASO Biotechnology Co., Ltd.
2024-03-27 – 2030-12 · Multiple Myeloma
What this study did
NCT07910903 · Keymed Biosciences Co.Ltd
2026-12 – 2030-11 · Multiple Myeloma (MM)
What this study did
NCT07933432 · Qilu Pharmaceutical Co., Ltd.
2026-12-30 – 2030-05-21 · Relapsed or Refractory Multiple Myeloma
What this study did
NCT07452198 · Genrix (Shanghai) Biopharmaceutical Co., Ltd.
2026-03-09 – 2030-03 · Multiple Myeloma
What this study did
NCT07138209 · Qilu Pharmaceutical Co., Ltd.
2025-11-07 – 2029-12 · Relapsed or Refractory Multiple Myeloma
What this study did
NCT07579351 · Semnur Pharmaceuticals, Inc.
2027-02 – 2029-04 · Lumbosacral Radicular Pain
What this study did
NCT07579234 · Shandong New Time Pharmaceutical Co., LTD
2026-01-25 – 2029-01-25 · Relapsed or Refractory Multiple Myeloma (RRMM)
What this study did
NCT06230224 · Regeneron Pharmaceuticals
2024-02-15 – 2028-05-29 · B-Cell Non-Hodgkin Lymphoma (B-NHL)
What this study did
NCT07413809 · The Affiliated People's Hospital of Ningbo University
2025-10-31 – 2027-09 · Multiple Myeloma
What this study did
NCT07327216 · Affiliated Hospital of Guangdong Medical University
2022-08-15 – 2027-07-01 · Nasopharyngeal Carcinoma (NPC)
What this study did
NCT06361329 · First Affiliated Hospital of Zhejiang University
2024-04-03 – 2027-03-31 · ETP-ALL
What this study did
NCT04162210 · GlaxoSmithKline
2020-04-02 – 2027-03-11 · Multiple Myeloma
What this study did
NCT06750458 · Tanta University
2025-01-20 – 2026-09-20 · Glioma, Dapagliflozin (Forxiga), Dexamethasone
What this study did
NCT07426081 · Patel Hospital, Pakistan
2025-06-01 – 2025-11-15 · Postoperative Nausea and Vomiting
What this study did
NCT06331520 · Fudan University
2024-05-01 – 2025-08-30 · Chemotherapy-induced Nausea and Vomiting, Highly Emetogenic Chemotherapy
What this study did
NCT00408005 · National Cancer Institute (NCI)
2007-01-30 – 2025-03-31 · T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
What this study did
NCT05675319 · Universitätsklinikum Hamburg-Eppendorf
2023-03-03 – 2025-03-21 · Multiple Myeloma
What this study did
NCT01093196 · Fondazione EMN Italy Onlus
2009-10 – 2024-07-01 · Multiple Myeloma
What this study did
NCT05805800 · Xingchen Peng
2023-04-15 – 2024-05-15 · Chemotherapy-induced Nausea and Vomiting
What this study did
NCT05242874 · Henan Cancer Hospital
2022-02-01 – 2023-08-15 · Chemotherapy-induced Nausea and Vomiting
What this study did
NCT02085655 · Huiqiang Huang
2013-04-25 – 2022-12-31 · Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
What this study did
NCT02393859 · Amgen
2015-11-10 – 2022-11-21 · Leukemia, Acute Lymphoblastic
What this study did
NCT04437017 · Fifth Affiliated Hospital, Sun Yat-Sen University
2020-02-03 – 2022-07-01 · Chemotherapy-induced Nausea and Vomiting
What this study did
NCT04636671 · University of Trieste
2021-04-14 – 2022-05-04 · Covid19, Viral Pneumonia Human Coronavirus, Severe Acute Respiratory Syndrome
What this study did
NCT04123561 · Taiwan Liposome Company
2019-11-26 – 2022-02-03 · Osteoarthritis of the Knee
What this study did
NCT04970719 · Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders
2021-07-10 – 2021-12 · COVID-19 Pneumonia
What this study did
NCT02556424 · Nantes University Hospital
2016-01 – 2021-02-15 · Inflammatory Macular Edema
What this study did
NCT04060771 · Universidade Federal Fluminense
2018-08-01 – 2020-07-01 · Anesthesia, Strabismus, PONV
What this study did
NCT02909478 · Sun Yat-sen University
2017-09-01 – 2019-12-31 · Chemotherapy-induced Nausea and Vomiting, Colorectal Cancer
What this study did
NCT02912702 · Beijing Friendship Hospital
2016-09 – 2019-09 · Hemophagocytic Lymphohistiocytosis
What this study did
Phase 2/3 (11)
Other / comorbidity
NCT07428369 · Regeneron Pharmaceuticals
2026-06-05 – 2038-05-21 · Multiple Myeloma (MM)
What this study did
NCT07852195 · ECOG-ACRIN Cancer Research Group
2027-01-06 – 2030-03-31 · Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
What this study did
NCT04061512 · University College, London
2020-02-03 – 2030-03 · Waldenstrom Macroglobulinemia
What this study did
NCT07542288 · The Second Affiliated Hospital of Hainan Medical University
2026-04-15 – 2028-06-30 · Brain Metastases From Solid Tumors
What this study did
NCT05096663 · SWOG Cancer Research Network
2022-03-15 – 2027-12-01 · Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT05367271 · Western Institute for Veterans Research
2022-08-23 – 2024-09-13 · Plantar Fasciitis
What this study did
NCT04862585 · Ohio State University Comprehensive Cancer Center
2021-10-07 – 2024-06-21 · Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Carcinoma, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
What this study did
NCT01442428 · University of Minnesota
2014-01 – 2016-06 · Immune Reconstitution Inflammatory Syndrome, Immune Reconstitution Syndrome, Tuberculosis, HIV-infection/Aids
What this study did
NCT00934739 · National Health Research Institutes, Taiwan
2007-06 – 2012-12 · Oral Cavity Cancer
What this study did
NCT01297686 · University of British Columbia
2011-05 – 2012-04 · Fasciitis, Plantar
What this study did
Phase 2 (22)
Other / comorbidity
NCT07764861 · Innovent Biologics (Suzhou) Co. Ltd.
2026-08-15 – 2031-06-30 · Multiple Myeloma
What this study did
NCT05469893 · Irene Ghobrial, MD
2022-08-10 – 2030-07-31 · High-risk Smoldering Multiple Myeloma, Smoldering Multiple Myeloma, Multiple Myeloma
What this study did
NCT07694089 · Akshitkumar MIstry
2026-10-01 – 2029-08-01 · High-grade Gliomas (HGG)
What this study did
NCT06643689 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-01-01 – 2028-12-31 · Esophageal Stricture, Esophageal Neoplasms
What this study did
NCT07814677 · Eye & ENT Hospital of Fudan University
2026-09-15 – 2028-12-15 · Sudden Hearing Loss
What this study did
NCT04635189 · University of Rochester
2021-07-27 – 2027-09-08 · Multiple Myeloma
What this study did
NCT07246070 · AIPING ZHOU
2025-12 – 2026-12 · Chemotherapy-Induced Nausea and Vomiting (CINV)
What this study did
NCT01917877 · Qingdao Central Hospital
2013-08-01 – 2025-12-30 · Pulmonary Fibrosis
What this study did
NCT04136743 · Kessler Foundation
2019-06-14 – 2024-04-30 · Spinal Cord Injuries, Tendinopathy, Rotator Cuff Tears, Shoulder Pain
What this study did
NCT05656521 · 101 Therapeutics
2023-01-31 – 2023-06 · COVID-19
What this study did
NCT04860518 · Faron Pharmaceuticals Ltd
2021-08-23 – 2022-04-04 · Covid19
What this study did
NCT04329650 · Judit Pich Martínez
2020-04-15 – 2021-02-26 · COVID-19
What this study did
NCT03778008 · Second Affiliated Hospital of Nanchang University
2018-12-21 – 2019-12-20 · Stomatitis
What this study did
NCT03740659 · NTC srl
2018-09-04 – 2018-12-06 · Cataract
What this study did
NCT02735317 · Yun-fei Xia
2016-04 – 2017-06 · Nasopharyngeal Neoplasms, Stomatitis
What this study did
NCT02482129 · Alcon Research
2015-07-17 – 2016-03-21 · Acute Anterior Uveitis
What this study did
NCT01908803 · Alcon Research
2013-12 – 2014-08 · Acute Otitis Media
What this study did
NCT02079649 · Alcon Research
2014-04 – 2014-07 · Allergic Conjunctivitis
What this study did
NCT01588925 · University of Sao Paulo General Hospital
2011-11 – 2014-01 · Hearing Loss
What this study did
NCT01001091 · Alcon Research
2009-12 – 2010-04 · Allergic Conjunctivitis
What this study did
NCT00663169 · Novartis
2008-04 – 2009-10 · Arthritis, Gouty
What this study did
Phase 1/2 (7)
Other / comorbidity
NCT07463807 · National Cancer Institute (NCI)
2027-04-12 – 2029-03-31 · Recurrent Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT07404709 · The Affiliated Hospital of Qingdao University
2026-02-28 – 2028-12-31 · Sudden Hearing Loss, Extracellular Vesicles
What this study did
NCT06536491 · Eclipse Life Sciences, Inc.
2024-08-19 – 2026-12-31 · Diabetic Macular Edema
What this study did
NCT07906925 · Tanta University
2026-10-05 – 2026-11-20 · Irreversible Pulpitis
What this study did
NCT04537026 · University of Utah
2021-06-16 – 2025-07-01 · Lumbar Spinal Stenosis
What this study did
NCT04150965 · Multiple Myeloma Research Consortium
2020-07-10 – 2024-08-30 · Multiple Myeloma, Relapsed Refractory Multiple Myeloma
What this study did
NCT01027650 · Allergan
2010-03 – 2013-02 · Macular Edema, Retinal Vein Occlusion
What this study did
Phase 1 (5)
Other / comorbidity
NCT07353593 · Ashraf elanzy
2023-10-01 – 2025-04-30 · Impacted Mandibular Third Molar Extraction
What this study did
NCT05142098 · Dow University of Health Sciences
2022-01-01 – 2022-08-01 · Effect of Drug
What this study did
NCT01711671 · Leap Therapeutics, Inc.
2013-05 – 2015-07 · Multiple Myeloma
What this study did
NCT00884546 · Bristol-Myers Squibb
2009-07 – 2012-03 · Advanced Cancer, Various, NOS
What this study did
Phase 4 (34)
Other / comorbidity
NCT04910503 · Centre Hospitalier Universitaire Dijon
2021-10-29 – 2030-04 · Diabetic Macular Edema
What this study did
NCT05716945 · Maastricht University Medical Center
2024-07-29 – 2029-03 · Pseudophakic Bullous Keratopathy, Fuchs' Endothelial Dystrophy, Intraocular Pressure
What this study did
Isa-VRD in TIE HRMMnot yet recruiting
NCT07334535 · Peking Union Medical College Hospital
2026-01-30 – 2029-01 · Multiple Myeloma
What this study did
NCT06118710 · Erasmus Medical Center
2024-06-25 – 2027-08-01 · Cancer
What this study did
NCT07254416 · Tianjin Medical University Cancer Institute and Hospital
2025-12-15 – 2027-06-30 · Breast Cancer Patients Treated With T-DXd
What this study did
NCT07638527 · Faisalabad Medical University
2026-09 – 2027-04 · Postoperative Nausea and Vomiting
What this study did
NCT05522465 · Fujian Medical University Union Hospital
2022-10-11 – 2026-08-31 · Immune Thrombocytopenia, Glucocorticoids, Child, Only
What this study did
NCT05936528 · Mansoura University Hospital
2025-09-29 – 2026-07-05 · Critical Illness
What this study did
NCT07078786 · Rawalpindi Medical College
2025-07-13 – 2025-10-15 · Cardiotocography, Steroids
What this study did
NCT06173466 · Zhejiang Cancer Hospital
2023-12-15 – 2024-05-30 · Liver Cancer
What this study did
NCT05861297 · Nahda University
2020-05-05 – 2024-04-02 · Immune Thrombocytopenia Purpura
What this study did
NCT03999125 · Sudhalkar Eye Hospital
2019-06-25 – 2023-06-24 · Clinically Significant Macular Edema Due to Diabetes Mellitus
What this study did
NCT04818749 · Zealand University Hospital
2021-06-02 – 2023-05-17 · Anesthesia, Local
What this study did
NCT04126278 · NYU Langone Health
2020-12-01 – 2022-08-23 · Calcific Tendinitis
What this study did
NCT05062681 · Cairo University
2021-09-15 – 2022-03-15 · COVID-19 Pandemic
What this study did
NCT04780581 · Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
2021-02-01 – 2021-11-09 · Corona Virus Infection
What this study did
NCT04103684 · Assiut University
2020-03-30 – 2021-08-30 · Encephalitis, Viral
What this study did
NCT05004753 · Mateon Therapeutics
2020-09-30 – 2021-04-30 · Covid19
What this study did
NCT04047446 · Hospital for Special Surgery, New York
2019-07-11 – 2021-03-19 · Shoulder Pain
What this study did
NCT03403517 · Copenhagen University Hospital, Rigshospitalet
2017-12-11 – 2020-09-28 · Complication, Postoperative
What this study did
NCT02833116 · Basque Health Service
2016-06 – 2020-06 · Chronic Pain
What this study did
NCT04737980 · Hospital for Special Surgery Florida
2019-07-18 – 2020-03-18 · Rotator Cuff Tears, Shoulder Pain
What this study did
NCT02624856 · Albany Medical College
2015-11 – 2020-01-01 · Osteoarthritis, Pain, Postoperative
What this study did
NCT03833947 · Aligarh Muslim University
2019-03-15 – 2019-12-30 · Anesthesia, Anesthesia; Adverse Effect, Anesthesia Intubation Complication
What this study did
NCT03317847 · Azienda USL Reggio Emilia - IRCCS
2017-10-16 – 2019-12-21 · Inflammation Eye
What this study did
NCT04075227 · Wannisa Suphachearabhan
2015-10-16 – 2019-03-02 · Recurrent Pterygium of Eye, Steroid-Induced Glaucoma
What this study did
NCT01990781 · B.P. Koirala Institute of Health Sciences
2013-12 – 2016-01 · Postoperative Sore Throat, Cough, Hoarseness
What this study did
NCT01660867 · Seoul National University Hospital
2012-08 – 2014-12 · Acute Bronchiolitis
What this study did
NCT01580020 · Novartis Pharmaceuticals
2012-05 – 2014-10 · Retinal Vein Occlusion
What this study did
NCT00588835 · Radboud University Medical Center
2008-03 – 2010-01 · Tumor
What this study did
NCT01211327 · University Hospital, Ghent
2008-07 – 2008-11 · Vernal Keratoconjunctivitis
What this study did
NCT00447577 · Bausch & Lomb Incorporated
2007-01 – 2007-06 · Blepharokeratoconjunctivitis
What this study did
NCT00532961 · Bausch & Lomb Incorporated
2005-02 – 2005-06 · Inflammation
What this study did
Early phase / not applicable (16)
Other / comorbidity
NCT07743827 · Alexandria University
2026-05-10 – 2027-10-15 · Olanzapine, Breast Cancer, Dexamethasone
What this study did
NCT07773220 · Khyber Teaching Hospital
2026-09-01 – 2027-02-28 · Cesarean Section Complications
What this study did
NCT07509866 · Huazhong University of Science and Technology
2026-04-09 – 2026-09-08 · Total Knee Anthroplasty, Nerve Block, Ropivacaine, Liposomal Bupivacaine
What this study did
NCT07628166 · Irfan Üstündağ
2026-03-02 – 2026-04-09 · Impacted Mandibular Third Molar Extraction, Postoperative Pain Control, Postoperative Edema and Pain
What this study did
NCT07691684 · University Of Anbar
2025-12-10 – 2026-04-09 · Temporomandibular Joint Disorders, Temporomandibular Joint Internal Derangement, Temporomandibular Joint Dysfunction Syndrome
What this study did
NCT06900777 · Xijing Hospital
2025-04-01 – 2026-04-01 · Vitiligo, Child, Progressive Disease
What this study did
NCT06949488 · Al-Azhar University
2024-12-01 – 2025-07-30 · Upper Limb Surgery, Brachial Plexus Blockade
What this study did
NCT06090500 · Ain Shams University
2023-03-20 – 2024-01-30 · Post-endodontic Pain
What this study did
NCT05717374 · Mansoura University
2023-02-13 – 2023-12-01 · Caudal Block
What this study did
NCT04519385 · South Valley University
2020-03-01 – 2020-08-05 · Pneumonia, Viral
What this study did
NCT03603119 · Institute of Liver and Biliary Sciences, India
2018-05-01 – 2019-11-15 · Postoperative Nausea and Vomiting
What this study did
NCT02478047 · Tianjin University of Traditional Chinese Medicine
2015-06 – 2016-09 · Chemotherapy-induced Nausea and Vomiting
What this study did
NCT02665533 · Federal University of the Valleys of Jequitinhonha and Mucuri
2016-01 – 2016-07 · Pain, Edema, Trismus
What this study did
NCT01885481 · Seoul National University Bundang Hospital
2013-10 – 2015-04 · Back Pain, Neck Pain
What this study did
NCT02224170 · Yonsei University
2014-11 – 2015-03 · Gallbladder Polyp, Asymptomatic Gallstones Without Cholecystitis
What this study did
Studied as part of a combination product (1)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 4 (1)
Other / comorbidity
NCT00190099 · Far Eastern Memorial Hospital
2003-01 – 2003-12 · Vessel Restenosis
What this study did
Appears in other studies (98)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (37)
Other / comorbidity
NCT06888817 · The Netherlands Cancer Institute
2025-06-19 – 2030-07 · Radiation Necrosis, High Grade Glioma (III or IV), Brain Metastasases, Radiation Toxicity, Radiation Effect, Radiation Injury, Radiation Injuries
What this study did
NCT05681260 · Children's Cancer Group, China
2023-02-06 – 2029-12-31 · T-cell Lymphoblastic Lymphoma
What this study did
NCT06382948 · MedSIR
2024-12-05 – 2028-04 · Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, ESR1 Gene Mutation
What this study did
NCT04504825 · Alexion Pharmaceuticals, Inc.
2020-08-25 – 2027-10-22 · AL Amyloidosis
What this study did
NCT07395232 · Dompé Farmaceutici S.p.A
2025-12-01 – 2027-05 · Atopic Keratoconjunctivitis
What this study did
NCT04512235 · Alexion Pharmaceuticals, Inc.
2020-11-03 – 2027-04-08 · AL Amyloidosis
What this study did
NCT06208917 · Yizhuo Zhang
2023-07-09 – 2027-01-31 · Pediatric Solid Tumor, Unspecified, Protocol Specific
What this study did
NCT01208662 · Paul Richardson, MD
2010-09 – 2026-12 · Multiple Myeloma
What this study did
NCT03578081 · Alliance for Clinical Trials in Oncology
2018-11-20 – 2023-05-01 · Malignant Neoplasm
What this study did
NCT02755597 · AbbVie
2016-07-11 – 2022-08-15 · Relapsed/Refractory Multiple Myeloma
What this study did
NCT00651261 · Alliance for Clinical Trials in Oncology
2008-04 – 2022-03-28 · Leukemia
What this study did
NCT00549848 · St. Jude Children's Research Hospital
2007-10-29 – 2022-03-26 · Acute Lymphoblastic Leukemia
What this study did
NCT01564537 · Takeda
2012-08-01 – 2022-02-08 · Relapsed Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT03252457 · Shandong University
2018-09-01 – 2021-12-01 · Purpura, Thrombocytopenic, Idiopathic, Immune Thrombocytopenia
What this study did
NCT04788654 · Gangnam Severance Hospital
2021-03-17 – 2021-07-31 · Laparoscopic Cholecystectomy
What this study did
NCT03674294 · Sun Yat-sen University
2015-08-04 – 2020-06-01 · Gastrointestinal Neoplasms, Chemotherapy-induced Nausea and Vomiting
What this study did
NCT02116530 · Alliance for Clinical Trials in Oncology
2014-08-20 – 2017-06-15 · Hematopoietic/Lymphoid Cancer, Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT02519842 · Merck Sharp & Dohme LLC
2015-09-14 – 2017-02-24 · Chemotherapy-induced Nausea and Vomiting
What this study did
NCT01470131 · AB Science
2011-05 – 2017-02-01 · Multiple Myeloma
What this study did
NCT01023308 · Novartis Pharmaceuticals
2009-12-21 – 2015-07-30 · Multiple Myeloma
What this study did
NCT00553059 · M.D. Anderson Cancer Center
2008-05 – 2014-08 · Chemotherapy-induced Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT01499849 · Tesaro, Inc.
2012-02 – 2014-05 · Chemotherapy-induced Nausea and Vomiting
What this study did
NCT01500213 · Tesaro, Inc.
2012-02 – 2014-03 · Chemotherapy-induced Nausea and Vomiting
What this study did
NCT01500226 · Tesaro, Inc.
2012-02 – 2014-02 · Chemotherapy-induced Nausea and Vomiting
What this study did
NCT02351622 · Shandong University
2012-09 – 2013-12 · Immune Thrombocytopenia
What this study did
NCT01002248 · AEterna Zentaris
2009-12 – 2013-03 · Multiple Myeloma
What this study did
NCT00064038 · SWOG Cancer Research Network
2004-11 – 2012-05 · Multiple Myeloma, Plasma Cell Neoplasm
What this study did
NCT00532155 · Sanofi
2007-09 – 2011-10 · Carcinoma, Non Small Cell Lung
What this study did
NCT00952341 · Merck Sharp & Dohme LLC
2009-08-25 – 2010-05-05 · Chemotherapy-induced Nausea and Vomiting (CINV)
What this study did
NCT00601172 · GlaxoSmithKline
2008-03-10 – 2009-04-13 · Nausea and Vomiting, Chemotherapy-Induced
What this study did
NCT00770562 · Hoffmann-La Roche
2005-07 – 2008-07 · Idiopathic Thrombocytopenic Purpura
What this study did
NCT00002548 · SWOG Cancer Research Network
1994-01 – 2006-11 · Multiple Myeloma
What this study did
Phase 2/3 (2)
Other / comorbidity
NCT02529774 · Ye Xu
2015-09 – 2021-09 · Resected Liver Metastases From Colorectal Cancer
What this study did
NCT02169882 · Universitas Padjadjaran
2014-12-01 – 2017-05-05 · Tuberculosis, Meningeal
What this study did
Phase 2 (20)
Other / comorbidity
NCT07064889 · Peking University People's Hospital
2025-07-30 – 2027-12-30 · Immune Thrombocytopenia
What this study did
NCT07065968 · Peking University People's Hospital
2025-08-19 – 2027-12-30 · Immune Thrombocytopenia (ITP)
What this study did
NCT05369364 · Peking University People's Hospital
2022-06-01 – 2026-06-01 · Immune Thrombocytopenia
What this study did
NCT06241547 · Peking Union Medical College Hospital
2024-02-05 – 2026-05-13 · Postoperative Nausea and Vomiting
What this study did
NCT05932524 · Peking University People's Hospital
2023-07-07 – 2025-06 · Immune Thrombocytopenia
What this study did
NCT06176235 · Peking University People's Hospital
2023-12-19 – 2025-05-12 · Immune Thrombocytopenia
What this study did
NCT04346654 · Novartis Pharmaceuticals
2020-10-09 – 2023-09-22 · Immune Thrombocytopenia (ITP)
What this study did
NCT04747080 · Peking University People's Hospital
2021-03-01 – 2023-07-01 · ITP, Immune Thrombocytopenia
What this study did
NCT04561180 · Evergreen Therapeutics, Inc.
2022-03-04 – 2023-05-01 · COVID-19 Pneumonia
What this study did
NCT04001725 · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
2019-10-15 – 2022-03-31 · Brain Metastases, Melanoma, Lung Cancer, Breast Cancer
What this study did
NCT04265534 · Calithera Biosciences, Inc
2020-07-24 – 2022-02-09 · Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung, KEAP1 Gene Mutation, NRF2 Gene Mutation, NFE2L2 Gene Mutation
What this study did
NCT04476979 · Assistance Publique - Hôpitaux de Paris
2020-07-16 – 2021-08-11 · Coronavirus Infection, SARS (Severe Acute Respiratory Syndrome), Virus Diseases, Coronaviridae Infections, Nidovirales Infections, RNA Virus Infections, Respiratory Tract Infections, Respiratory Tract Disease
What this study did
NCT04217148 · Peking University People's Hospital
2020-01-01 – 2020-06-30 · Immune Thrombocytopenia
What this study did
NCT02628704 · Karyopharm Therapeutics Inc
2015-12 – 2018-06 · Multiple Myeloma
What this study did
NCT01691690 · Nationwide Children's Hospital
2012-10 – 2016-07 · Adenotonsillitis, Tonsillitis
What this study did
NCT01989325 · Pfizer
2013-11 – 2016-05 · Advanced Multiple Myeloma
What this study did
NCT01976195 · Shandong University
2013-10 – 2014-12 · Immune Thrombocytopenia
What this study did
NCT01602224 · Eli Lilly and Company
2012-07 – 2014-07 · Multiple Myeloma
What this study did
NCT01337752 · Novartis Pharmaceuticals
2012-01 – 2013-05 · Multiple Myeloma, Renal Insufficiency
What this study did
Phase 1/2 (8)
Other / comorbidity
NCT06437054 · Seoul National University Hospital
2026-12-15 – 2028-09-30 · Hearing Loss, Sensorineural, Hearing Loss, Sudden, Intratympanic Injection
What this study did
NCT04663347 · Genmab
2020-11-03 – 2027-09-30 · Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
What this study did
NCT03970655 · University of Florida
2019-09-25 – 2026-02-02 · Chronic Rhinosinusitis (Diagnosis)
What this study did
NCT04766853 · Seoul National University Hospital
2021-07-22 – 2024-07-19 · Hearing Loss, Sudden, Hearing Loss, Ototoxic, Hearing Loss, Noise-Induced, Meniere Disease
What this study did
NCT02928029 · Bayer
2017-02-10 – 2019-03-20 · Multiple Myeloma
What this study did
NCT02518113 · Eli Lilly and Company
2015-10-01 – 2018-01-15 · T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoblastic Lymphoma
What this study did
NCT00473746 · Janssen Research & Development, LLC
2006-06 – 2012-12 · Prostate Neoplasms
What this study did
NCT00299182 · M.D. Anderson Cancer Center
2006-03 – 2012-04 · Lymphoma
What this study did
Phase 1 (1)
Other / comorbidity
NCT06142396 · Augusta University
2024-11-01 – 2027-11-01 · Multiple Myeloma, Renal Failure
What this study did
Phase 4 (14)
Other / comorbidity
NCT03760835 · Federico II University
2016-08-11 – 2027-12-31 · Congenital Adrenal Hyperplasia
What this study did
NCT06489626 · F. Johannes Plate
2025-11-01 – 2027-12-01 · Arthritis Knee, Knee Osteoarthritis, Pain, Postoperative
What this study did
NCT07639723 · Endeavor Health
2026-07 – 2027-08 · PONV
What this study did
NCT07097493 · Wake Forest University Health Sciences
2027-02 – 2027-06 · Knee Arthroplasty, Total
What this study did
NCT05518383 · Federal Research Institute of Pediatric Hematology, Oncology and Immunology
2022-05-25 – 2027-05-16 · Non-hodgkin Lymphoma,B Cell, Burkitt Lymphoma, Primary Mediastinal Lymphoma, Primary CNS Lymphoma, Diffuse Large B-cell Lymphoma
What this study did
NCT05072262 · Oslo University Hospital
2022-11-25 – 2026-10 · Descemet Stripping Automated Endothelial Keratoplasty (DSAEK), Descemet Membrane Endothelial Keratoplasty (DMEK)
What this study did
NCT04826237 · Northwestern University
2023-02-09 – 2025-10-30 · Sudden Sensorineural Hearing Loss
What this study did
NCT05667324 · University of Florida
2023-04-12 – 2025-02-28 · Deviated Nasal Septum
What this study did
NCT04083066 · Mingzhi Zhang
2019-09-05 – 2024-04-01 · Primary Central Nervous System Lymphoma
What this study did
NCT03630367 · Assiut University
2018-10-03 – 2020-10 · Premature Birth
What this study did
NCT03057015 · University of Vermont
2017-05-22 – 2019-02-28 · Postoperative Pain
What this study did
NCT02292082 · Hospital for Special Surgery, New York
2014-11 – 2016-08 · Osteoarthritis
What this study did
NCT02431286 · Instituto do Cancer do Estado de São Paulo
2014-10 – 2015-12 · Postoperative Nausea and Vomiting
What this study did
NCT02433899 · Universidade Federal Fluminense
2010-10 – 2012-04 · Gingival Recession
What this study did
Early phase / not applicable (16)
Other / comorbidity
NCT07216820 · University of North Carolina, Chapel Hill
2026-01-21 – 2027-11-15 · Shoulder Surgery, Obesity
What this study did
NCT07883616 · Zagazig University
2025-10-01 – 2027-01-01 · Postoperative Pain After Spinal Surgery
What this study did
NCT06479317 · Yunfeng Cheng
2024-04-24 – 2026-12 · Immune Thrombocytopenia With Positive ANA Antibodies
What this study did
NCT07104097 · Papa Giovanni XXIII Hospital
2025-10-06 – 2026-07-02 · Hip Surgery
What this study did
NCT02473042 · M.D. Anderson Cancer Center
2016-03-01 – 2024-11-26 · Post-Operative Nausea and Vomiting, Breast Cancer
What this study did
NCT04607447 · Huashan Hospital
2020-08-04 – 2023-12-30 · Chronic Subdural Hematoma
What this study did
NCT03902782 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2019-06-26 – 2021-06-20 · Lung Cancer, Lung Diseases
What this study did
NCT03041935 · Alberta Children's Hospital
2015-09-01 – 2019-01-01 · Testicle Undescended, Pain, Postoperative
What this study did
NCT02644720 · Sun Yat-sen University
2014-01 – 2019-01 · Cataract
What this study did
NCT03041948 · Alberta Children's Hospital
2015-09-01 – 2018-09-01 · Hernia, Inguinal, Pain, Postoperative
What this study did
NCT02403037 · The Hong Kong Polytechnic University
2015-07 – 2016-10 · Breast Neoplasms, Nausea, Vomiting
What this study did
NCT02252419 · Seoul National University Hospital
2014-10 – 2015-03 · Pharyngitis
What this study did
NCT02855866 · Centre Hospitalier Universitaire Dijon
2013-09-03 – 2015-02-20 · Thyroidectomy, Post-operative Swallowing Disorders
What this study did
NCT01739985 · Assistance Publique - Hôpitaux de Paris
2010-12 – 2014-05 · Postoperative Vomiting
What this study did
NCT02550119 · University of Southern California
2006-04-19 – 2010-04-01 · Malignant Digestive System Neoplasm, Nausea and Vomiting
What this study did
NCT00187070 · St. Jude Children's Research Hospital
1997-12 – 2001-07 · Lymphoma, Large Cell, Lymphoma, Non-Hodgkin
What this study did

Competitive landscape

This mechanism is crowded: 23 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Ulcerative Colitis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Dexamethasone: this drugApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Adalimumab (Humira)ApprovedMonoclonal antibodyTNF-alphaPartial signal
NCT00408629: Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8 (Week 8): Adalimumab 160/80/40 16.5% vs Placebo 9.3%; p=0.019 (Adalimumab 160/80/40 vs Placebo)
NCT02065557: Induction (Week 8, ITT-E, Main Study): I-SD 43.3% vs external placebo 19.83% (p=0.382, NS); I-HD 59.6% vs external placebo (p<0.001); combined I-SD+I-HD 53.2% (p<0.001). Maintenance (Week 52, mITT-E): M-PL 33.3% (n=12, descriptive only); M-SD 29.0% vs external placebo 18.37% (p=0.382, NS); M-HD 45.2% (p<0.001); combined M-SD+M-HD 37.1% (p<0.001).
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Albuterol / Budesonide (Airsupra)
Approved(overall)
CombinationBeta-2 adrenergic receptor, Glucocorticoid receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Balsalazide Disodium (Colazal)
ApprovedUS marketing discontinued
Small moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Beclomethasone (QVAR)
Approved(overall)
Small moleculeGlucocorticoid receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Betamethasone Dipropionate Emollient Spray (Sernivo)
Approved(overall)
Small moleculeGlucocorticoid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Budesonide (targeted-Release) (TARPEYO / Nefecon)
Approved(overall)
Small moleculeGlucocorticoid receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Budesonide (Uceris Rectal Foam)ApprovedSmall moleculeGlucocorticoid receptorReliable signalNo reviewed efficacy summary in this indication
Budesonide MMX (Uceris)ApprovedSmall moleculeGlucocorticoid receptorPartial signal
NCT01532648: Registered primary, clinical remission at day 56 (UCDAI rectal bleeding and stool frequency subscores of 0), budesonide MMX 9 mg vs placebo added to oral mesalamine: 56/230 vs 52/228 (CT.gov); similar in both groups, p=0.70 (Rubin 2017). Combined clinical and endoscopic remission at week 8: 13.0% vs 7.5%, p=0.049. missed
Ciclesonide (Alvesco)
Approved(overall)
Small moleculeGlucocorticoid receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Dexamethasone (Dextenza)
Approved(overall)
Small moleculeGlucocorticoid receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Etrasimod (Velsipity)ApprovedSmall moleculeS1P receptorReliable signal
NCT03945188: Percentage of Participants Achieving Clinical Remission at Week 12 (At Week 12): Etrasimod 2 mg 27.0% vs Placebo 7.4%; p=<0.001 (Etrasimod 2 mg vs Placebo)
NCT03996369: Percentage of Participants Achieving Clinical Remission (Week 12): Etrasimod 2 mg 24.8% vs Placebo 15.2%; p==0.026 (Etrasimod 2 mg vs Placebo)
Fluticasone Furoate (Arnuity Ellipta)
Approved(overall)
Small moleculeGlucocorticoid receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Fluticasone Furoate / Umeclidinium / Vilanterol (Trelegy Ellipta)
Approved(overall)
Small moleculeMuscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination)
Reliable signal(overall)
No reviewed efficacy summary in this indication
Fluticasone Furoate / Vilanterol (Breo Ellipta)
Approved(overall)
Small moleculeBeta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Fluticasone Propionate
Approved(overall)
Small moleculeGlucocorticoid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Fluticasone Propionate / Salmeterol (Advair HFA)
Approved(overall)
CombinationGlucocorticoid receptor / Beta-2 adrenergic receptor, Beta-2 adrenergic receptor, Glucocorticoid receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Golimumab (Simponi)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT01863771: Number of Participants Who Achieved Clinical Response Through Maintenance-Week 54 Measured Using the Mayo Score (Up to Week 54): Placebo 6/31 (19.4%) (95% CI 5.4-33.3) vs Golimumab 18/32 (56.3%) (95% CI 39.1-73.4)
NCT00488631: Number of Participants in Clinical Response Through Week 54 (Induction Baseline, Week 0 through Week 54): Golimumab Induction Responders (GLM-I-Rsp)-Placebo Maintenance 48/154 (31.2%) vs GLM-I-Rsp-Golimumab 50 mg Maintenance 71/151 (47.0%) vs GLM-I-Rsp-Golimumab 100 mg Maintenance 75/151 (49.7%); p=0.010 (Golimumab Induction Responders (GLM-I-Rsp)-Placebo Maintenance vs GLM-I-Rsp-Golimumab 50 mg Maintenance), p=<0.001 (Golimumab Induction Responders (GLM-I-Rsp)-Placebo Maintenance vs GLM-I-Rsp-Golimumab 100 mg Maintenance)
Guselkumab (Tremfya)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT05528510: Percentage of Participants in Clinical Remission at Week 12 (Week 12): Placebo 6.5 Percentage of participants (95% CI 2.4 to 10.6) | Combined Guselkumab 400 mg 27.6 Percentage of participants (95% CI 22.4 to 32.8)
QUASAR/GALAXI: superior to ustekinumab on pooled endoscopic endpoints
Halobetasol Propionate Foam (Lexette)
ApprovedUS marketing discontinued (overall)
Small moleculeGlucocorticoid receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Halobetasol Propionate Lotion (Bryhali)
Approved(overall)
Small moleculeGlucocorticoid receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Hydrocortisone (Cortenema)ApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Hydrocortisone Acetate (Cortifoam)ApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Infliximab (Remicade)ApprovedMonoclonal antibodyTNF-alphaWeak signal
NCT01585155: Percent of Patients Who Achieved CAI Remission (Weeks 2, 6, 8, 10, 14, 18, 22, 26, 30, and the last time point during the period from administration of the study drug to Week 30): TA-650 — Weeks 2: 60%; Weeks 6: 80%; Weeks 8: 80%; Weeks 10: 77.8%; Weeks 14: 87.5%; Weeks 18: 87.5%; Weeks 22: 64.3%; Weeks 26: 85.7%; Weeks 30: 64.3%; The last time point: 42.9%
NCT00336492: The Number of Participants With Clinical Response at Week 8 (Week 8): Infliximab 5 mg/kg 44/60 (73.3%)
Infliximab-Abda (Renflexis)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Axxq (Avsola)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Dyyb (Inflectra)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Dyyb (Zymfentra)ApprovedMonoclonal antibodyTNF-alphaReliable signalNo reviewed efficacy summary in this indication
Infliximab-Qbtx (Ixifi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Mesalamine (Apriso)ApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Mesalamine (Canasa)ApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Mesalamine (Lialda)ApprovedSmall moleculeAminosalicylateReliable signal
NCT00151892: Endoscopic Remission of Ulcerative Colitis (UC) at 6 Months (6 Months): SPD476 83.7 percent of participants | Asacol 81.5 percent of participants
Mesalamine (Pentasa)ApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Mesalamine (Rowasa)ApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
MethylprednisoloneApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Mirikizumab (Omvoh)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT03524092: Percentage of Participants in Clinical Remission at Week 40 (Mirikizumab Induction Responders) (Week 40): Maintenance Period: Miri IR - 200 mg Miri SC 49.9% (95% CI 44.7 to 55) vs Maintenance Period: Miri IR - PBO SC 25.1% (95% CI 18.8 to 31.5)
NCT03518086: Percentage of Participants With Clinical Remission at Week 12 (Week 12): Placebo IV Q4W 13.3% (95% CI 6.9-19.6) vs 300 mg Mirikizumab IV Q4W 24.2% (95% CI 19.5-28.9); p=0.00006 (Placebo IV Q4W vs 300 mg Mirikizumab IV Q4W)
Olsalazine (Dipentum)ApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Ozanimod (Zeposia)ApprovedSmall moleculeS1P receptorReliable signal
NCT02435992: Percentage of Participants in Clinical Remission at 10 Weeks (At 10 Weeks): RPC1063 Cohort 1(Induction Period) 18.4% vs Placebo Cohort 1 (Induction Period) 6.0% vs RPC1063 Cohort 2 (Induction Period) 21.0%; p=0.0001 (RPC1063 Cohort 1(Induction Period) vs Placebo Cohort 1 (Induction Period))
NCT03915769: Clinical response at week 12: 52.9% (0.46 mg) and 61.5% (0.92 mg) vs 32.3% placebo.
Relacorilant (Lifyorli)
Approved(overall)
Small moleculeGlucocorticoid receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Risankizumab (Skyrizi)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
INSPIRE/COMMAND: clinical remission + endoscopic improvement met
NCT03398148: Sub-Study 1: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo Score (Week 12): Substudy 1, Induction Period 1: Double-blind Placebo IV 1/60 (1.7%) vs Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV 7/61 (11.5%) vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV 6/61 (9.8%) vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV 6/58 (10.3%) vs Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV 42/340 (12.4%); p=0.0324 (Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV), p=0.0460 (Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV), p=0.0397 (Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV)
SulfasalazineApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Tofacitinib (Xeljanz)ApprovedSmall moleculeJAK, JAK1/JAK3Reliable signal
NCT01458574: Percentage of Participants In Remission at Week 52 (Week 52): Tofacitinib 5 mg BID 34.3% vs Tofacitinib 10 mg BID 40.6% vs Placebo 11.1%; p=<0.0001 (Tofacitinib 5 mg BID vs Placebo), p=<0.0001 (Tofacitinib 10 mg BID vs Placebo)
NCT01458951: Percentage of Participants With Remission at Week 8 (Week 8): Tofacitinib 10 mg BID 16.6% vs Placebo BID 3.6%; p=0.0005 (Tofacitinib 10 mg BID vs Placebo BID)
Upadacitinib (Rinvoq)ApprovedSmall moleculeJAK, JAK1Reliable signal
NCT03653026: Percentage of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8 (Week 8): Upadacitinib 45 mg 33.5% (95% CI 28.5-38.5) vs Placebo 4.1% (95% CI 1.1-7.1); p=<0.001 (Upadacitinib 45 mg vs Placebo)
NCT02819635: Substudy 1: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8 (At Week 8): SS1: Placebo 0% vs SS1: Upadacitinib 7.5 mg 8.5% vs SS1: Upadacitinib 15 mg 14.3% vs SS1: Upadacitinib 30 mg 13.5% vs SS1: Upadacitinib 45 mg 21.4%; p=0.049 (SS1: Placebo vs SS1: Upadacitinib 7.5 mg), p=0.010 (SS1: Placebo vs SS1: Upadacitinib 15 mg), p=0.007 (SS1: Placebo vs SS1: Upadacitinib 30 mg), p=<0.001 (SS1: Placebo vs SS1: Upadacitinib 45 mg)
Ustekinumab (Stelara)ApprovedMonoclonal antibodyIL-12 p40Reliable signal
NCT02407236: Induction Study - Number of Participants With Clinical Remission at Week 8 (As Per Global Definition) (Week 8): Induction Study (IS): Placebo Intravenous (IV) 17/319 (5.3%) vs IS: Ustekinumab 130 Milligram (mg) IV 50/320 (15.6%) vs IS: Ustekinumab Approximately 6 mg/kg IV 50/322 (15.5%); p=< 0.001 (Induction Study (IS): Placebo Intravenous (IV) vs IS: Ustekinumab 130 Milligram (mg) IV), p=< 0.001 (Induction Study (IS): Placebo Intravenous (IV) vs IS: Ustekinumab Approximately 6 mg/kg IV)
NCT04630028: Week 8 clinical remission 25% (27/107) after IV induction; the study's primary endpoint is week 52 remission in week 8 responders.
Ustekinumab-Aauz (Otulfi)Approved—IL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Aekn (Selarsdi)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Auub (Wezlana)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Hmny (Starjemza)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Srlf (Imuldosa)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Stba (Steqeyma)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Ttwe (Pyzchiva)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Vedolizumab (Entyvio)ApprovedMonoclonal antibodyα4β7 integrinReliable signal
NCT02497469: Percentage of Participants Who Achieved Clinical Remission (Week 52): Adalimumab SC, 160/80/40 mg 22.5% (95% CI 18.5-27.0) vs Vedolizumab IV 300 mg 31.3% (95% CI 26.7-36.2); p=0.0061 (Adalimumab SC, 160/80/40 mg vs Vedolizumab IV 300 mg)
NCT02611830: Percentage of Participants Achieving Clinical Remission at Week 52 (Week 52): Maintenance Phase: Induction IV + Placebo 14.3% (95% CI 6.4-26.2) vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC 46.2% (95% CI 36.5-56.2) vs Maintenance Phase: Induction IV + Vedolizumab 300 mg IV 42.6% (95% CI 29.2-56.8); p=<0.001 (Maintenance Phase: Induction IV + Placebo vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC)
Lodotra (Rayos)
US approval withdrawn(overall)
—Glucocorticoid receptor
Weak signal(overall)
No reviewed efficacy summary in this indication
Mesalamine (Asacol HD)US approval withdrawnSmall moleculeAminosalicylatePartial signalNo reviewed efficacy summary in this indication
AfimkibartPhase 3Monoclonal antibodyTL1APartial signal
NCT04090411: Induction Period: Percentage of Participants Who Achieved Clinical Remission at Week 14 (At Week 14): Induction Period: Placebo 11.6% (95% CI 5.77-22.88) vs Induction Period: PF-06480605 50 mg 25.5% (95% CI 15.44-37.19) vs Induction Period: PF-06480605 150 mg 23.3% (95% CI 14.98-33.98) vs Induction Period: PF-06480605 450 mg 23.9% (95% CI 16.58-32.06); p=0.0545 (Induction Period: Placebo vs Induction Period: PF-06480605 50 mg), p=0.0823 (Induction Period: Placebo vs Induction Period: PF-06480605 150 mg), p=0.0642 (Induction Period: Placebo vs Induction Period: PF-06480605 450 mg) missed
DuvakitugPhase 3Monoclonal antibodyTL1APartial signal
NCT05499130: UC cohort, clinical remission at week 14: 36% (450 mg) / 48% (900 mg) vs 20% placebo, placebo-adjusted 16% (p=.050) / 27% (p=.003). CD cohort, endoscopic response: 26.1% (low dose) / 47.8% (high dose) vs 13.0% placebo. P-values are one-sided at a 0.10 significance level.
Icotrokinra (Icotyde)Phase 3PeptideIL-23 receptorReliable signal
NCT06049017: Primary endpoint clinical response at Week 12: 63.5% with the highest icotrokinra dose vs 27% with placebo (p<0.001)
JNJ-78934804Phase 3CombinationIL-23 p19, TNF-alphanot yet gradedNo reviewed efficacy summary in this indication
MufemilastPhase 3Small moleculePDE4not yet gradedNo reviewed efficacy summary in this indication
ObefazimodPhase 3Small moleculemiR-124Reliable signal
NCT05535946: ABTECT maintenance, clinical remission at Week 44: placebo 10.4% (20), 25 mg 50.8% (98; placebo-adjusted +39.3%), 50 mg 51.3% (100; placebo-adjusted +40.3%), p<0.0001
NCT05507203: ABTECT-1 (NCT05507203), clinical remission at Week 8: placebo 2.5% (4/158), 25 mg 23.8% (38/160, p<0.0001), 50 mg 21.7% (69/318, p<0.0001; placebo-adjusted +19.3%)
PonesimodPhase 3Small moleculeS1P receptornot yet gradedNo reviewed efficacy summary in this indication
TulisokibartPhase 3Monoclonal antibodyTL1AReliable signal
NCT06052059: ATLAS-UC Study 2 (NCT06052059): tulisokibart met its primary endpoint of clinical remission (Modified Mayo Score) at week 12, plus key secondary endpoints.
NCT04996797: Remission 26% vs 1% placebo; +25pp (95% CI 14–37)
AC-101Phase 2Small moleculeRIPK2not yet gradedNo reviewed efficacy summary in this indication
ALTB-268Phase 2Monoclonal antibodyPSGL-1Weak signalNo reviewed efficacy summary in this indication
AmiselimodPhase 2Small moleculeS1P receptorReliable signal
NCT04857112: Change from baseline in modified Mayo Score at Day 85: amiselimod -2.3 vs placebo -1.6 (p=0.002)
ATH-063Phase 2Small moleculeG9A (EHMT2)Weak signalFeatured results are safety only in this race
BI 3032950Phase 2Monoclonal antibodyTREM-1not yet gradedNo reviewed efficacy summary in this indication
CU104Phase 2Small moleculeEndothelial barrier functionPartial signalNo reviewed efficacy summary in this indication
Dazucorilant
Phase 2(overall)
Small moleculeGlucocorticoid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
GarutadustatPhase 2Small moleculePHD1/2not yet gradedNo reviewed efficacy summary in this indication
HRS-7085Phase 2Small moleculeNCBP1/NCBP2 (nuclear cap-binding complex)Weak signalNo reviewed efficacy summary in this indication
IPG11406Phase 2Small moleculeEBI2Weak signalFeatured results are safety only in this race
Miricorilant
Phase 2(overall)
Small moleculeGlucocorticoid receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
MT-201Phase 2Biologic (subtype unspecified)—not yet gradedNo reviewed efficacy summary in this indication
MT-501Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
OmilancorPhase 2Small moleculeLANCL2Partial signal
NCT03861143: Clinical Remission (Week 12): BT-11 Low-dose (440 mg) 30.3% | BT-11 High-dose (880 mg) 31.8% vs Placebo 22.7%
ZotemtegrastPhase 2Small moleculeα4β7 integrinWeak signal
NCT05611671: Percentage of Participants in Clinical Remission as Determined Using the Modified Mayo Clinic Score (mMCS) (Week 12): MORF-057 200 mg BID 31.9% | MORF-057 100 mg BID 23.9% | MORF-057 100 mg QD-M 17.1% vs Placebo 24.3% missed
NCT05291689: Main Cohort: Change From Baseline to Week 12 in the Robarts Histopathology Index (RHI) Score (From baseline to 12 weeks): MORF-057 (Main Cohort) -6.4 score on a scale (Standard Deviation 11.18)
ICG318Phase 1/2Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
Remestemcel-L (Ryoncil)Phase 1/2Cell therapyAllogeneic MSC therapynot yet gradedNo reviewed efficacy summary in this indication
BDHK-2009Phase 1Small molecule—not yet gradedNo reviewed efficacy summary in this indication
ExoFloPhase 1Cell therapyMSC-derived exosomesWeak signalNo reviewed efficacy summary in this indication
LMT503Phase 1Small moleculeMacrophage polarization / Cellular metabolismnot yet gradedNo reviewed efficacy summary in this indication

Large race: only the 91 furthest-along competitors are listed; 40 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(426 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Dexamethasone to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (65)
November 2026 (12)
Phase 1Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-11 · NCT05560399 · CT.gov ↗
What to watch
Phase 1/2Relapsed/Refractory Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-11 · NCT04973605 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-11 · NCT06505369 · CT.gov ↗
What to watch
Phase 2Nausea and Vomiting Caused by ChemotherapyRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-11 · NCT07537699 · CT.gov ↗
What to watch
Phase 2Nausea and Vomiting Caused by Trastuzumab DeruxtecanRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-11 · NCT07537673 · CT.gov ↗
What to watch
Phase 2Nausea and Vomiting Caused by ChemotherapyRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-11 · NCT07537660 · CT.gov ↗
What to watch
Phase 2Multiple Myeloma, Plasma Cell LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-11 · NCT06517017 · CT.gov ↗
What to watch
Phase 1Non-Hodgkin LymphomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-11-30 · NCT05688475 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-11-30 · NCT03989414 · CT.gov ↗
What to watch
Phase 2Mandible Fracture, Edema Face, Pain Management, Corticosteroid InjectionRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-11-30 · NCT07208799 · CT.gov ↗
What to watch
Phase 3Acute Lymphoblastic Leukemia, PediatricActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-11-30 · NCT03020030 · CT.gov ↗
What to watch
Early phase / not applicablePostoperative Nausea and Vomiting, Dexamethasone Palmitate, Open SurgeryRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-11-30 · NCT06997419 · CT.gov ↗
What to watch
December 2026 (53)
Phase 1Radiotracer, Hypertension, CholesterolRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12 · NCT04546126 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12 · NCT01562405 · CT.gov ↗
What to watch
Phase 1/2Ureteral Stent-Related SymptomRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12 · NCT06930690 · CT.gov ↗
What to watch
Phase 2Systemic AmyloidosisRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12 · NCT06342466 · CT.gov ↗
What to watch
Phase 2Lassa FeverRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12 · NCT06222723 · CT.gov ↗
What to watch
Phase 2NK/T Cell LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12 · NCT07000617 · CT.gov ↗
What to watch
Phase 2Myeloma, MultipleActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12 · NCT04009109 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12 · NCT02718833 · CT.gov ↗
What to watch
Phase 2/3Relapsed/Refractory Diffuse Large B-cell LymphomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12 · NCT04442022 · CT.gov ↗
What to watch
Phase 4Lumbar Disc HerniationRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12 · NCT04182997 · CT.gov ↗
What to watch
Phase 4AsthmaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12 · NCT07228052 · CT.gov ↗
What to watch
Phase 4Symptomatic Irreversible PulpitisNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12 · NCT07699315 · CT.gov ↗
What to watch
Phase 4Postoperative Pain, Arthroscopic Shoulder Surgery, Regional AnesthesiaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12 · NCT07795281 · CT.gov ↗
What to watch
Early phase / not applicablePost Spinal Anesthesia ShiveringNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12 · NCT06999070 · CT.gov ↗
What to watch
Early phase / not applicableLung Cancer, Surgery, Blood Pressure Management, Dexamethasone, Overall Survival, Postoperative ComplicationsRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12 · NCT04209218 · CT.gov ↗
What to watch
Early phase / not applicableWe Are Studying the Effects of Caudal Dexamethasone in Neonates Undergoing Inguinal Hernia RepairNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12 · NCT07609836 · CT.gov ↗
What to watch
Phase 1Post Operative PainEnrolling by invitationStudy of the molecule, not a specific product
Est. primary completion 2026-12-01 · NCT07380139 · CT.gov ↗
What to watch
Phase 1/2NKTCL, SelinexorRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-01 · NCT06559553 · CT.gov ↗
What to watch
Phase 1/2Acute Leukemia, Lymphoblastic Leukemia, Lymphoblastic LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-01 · NCT06207123 · CT.gov ↗
What to watch
Phase 2Precursor Cell Lymphoblastic Leukemia-LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-01 · NCT06387121 · CT.gov ↗
What to watch
Phase 2Plasma Cell LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-01 · NCT05979363 · CT.gov ↗
What to watch
Phase 4Cesarean SectionNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-01 · NCT06704139 · CT.gov ↗
What to watch
Early phase / not applicablePost Operative Urinary Retention, Spinal AneshtesiaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-01 · NCT07077850 · CT.gov ↗
What to watch
Early phase / not applicablePain, Interscalene Blocks, Dexamethasone, BupivacaineRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-01 · NCT07324499 · CT.gov ↗
What to watch
Phase 3Nausea and Vomiting Caused by ChemotherapyRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-06 · NCT07716176 · CT.gov ↗
What to watch
Phase 3Nausea and Vomiting Caused by Trastuzumab DeruxtecanRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-06 · NCT07716189 · CT.gov ↗
What to watch
Phase 3Nausea and Vomiting Caused by ChemotherapyRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-06 · NCT07716228 · CT.gov ↗
What to watch
Phase 3Hospital Acquired PneumoniaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-15 · NCT06269900 · CT.gov ↗
What to watch
Phase 4Dexamethasone, Spinal Anesthesia, AdjuvantRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-15 · NCT07819682 · CT.gov ↗
What to watch
Early phase / not applicableSymptomatic Irreversible Pulpitis (SIP), Dental PainRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-15 · NCT07672873 · CT.gov ↗
What to watch
Phase 2/3Facial Injuries, Pain, SwellingRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-20 · NCT07853664 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-28 · NCT03729804 · CT.gov ↗
What to watch
Phase 1/2Acute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma, Pre B-Cell Acute Lymphoblastic LeukaemiaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-30 · NCT03114865 · CT.gov ↗
What to watch
Phase 4Graves Disease, Hashimoto DiseaseRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-30 · NCT05435547 · CT.gov ↗
What to watch
Early phase / not applicableHip Osteoarthritis, Hip Pain ChronicRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-30 · NCT07327931 · CT.gov ↗
What to watch
Phase 1Recurrent Multiple Myeloma, Refractory Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT05981209 · CT.gov ↗
What to watch
Phase 1Lymphoma, B-CellActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT04161248 · CT.gov ↗
What to watch
Phase 1Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Relapsed Leukemia, Refractory LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT05495035 · CT.gov ↗
What to watch
Phase 1/2KeratoconusEnrolling by invitationStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT07388069 · CT.gov ↗
What to watch
Phase 1/2Postoperative Pain, Nausea and Vomiting, Postoperative, Dizziness, Constipation, Duration of Response, Narcotics Consumption …Active not recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT07099222 · CT.gov ↗
What to watch
Phase 1/2Recurrent Plasma Cell Myeloma, Refractory Plasma Cell MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT05514990 · CT.gov ↗
What to watch
Phase 2Relapsed/Refractory Large B-Cell LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT06489808 · CT.gov ↗
What to watch
Phase 2Colorectal Cancer MetastaticRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT05727163 · CT.gov ↗
What to watch
Phase 2Hodgkin LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT05180097 · CT.gov ↗
What to watch
Phase 2Blastic Plasmacytoid Dendritic Cell NeoplasmRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT04216524 · CT.gov ↗
What to watch
Phase 2Recurrent Multiple Myeloma, Refractory Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT04883242 · CT.gov ↗
What to watch
Phase 2LymphomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT02436707 · CT.gov ↗
What to watch
Phase 2Thrombosis, Deep Vein, Iliofemoral; ThrombosisRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT04862468 · CT.gov ↗
What to watch
Phase 3Hodgkin Lymphoma, AdultRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT04638790 · CT.gov ↗
What to watch
Phase 3Plasma Cell MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT01863550 · CT.gov ↗
What to watch
Phase 4Clavicle FractureNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT06692010 · CT.gov ↗
What to watch
Early phase / not applicableMultiple Myeloma, NeoplasmsActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT06924424 · CT.gov ↗
What to watch
Early phase / not applicableRadiation-Induced Intestinal InjuryRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT06410443 · CT.gov ↗
What to watch
2027 (169)
January 2027 (11)
Phase 2Amyloid, AL Amyloidosis, Refractory AL AmyloidosisActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-01 · NCT04270175 · CT.gov ↗
What to watch
Early phase / not applicablePain, Acute Post-Operative, Nausea and Vomiting, PostoperativeNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-01 · NCT07655908 · CT.gov ↗
What to watch
Phase 4Sacroiliac Joint Dysfunction, Sacro-Iliac SpondylosisRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-01-01 · NCT06268704 · CT.gov ↗
What to watch
Phase 4Arthropathy of KneeEnrolling by invitationStudy of the molecule, not a specific product
Est. primary completion 2027-01-01 · NCT06715709 · CT.gov ↗
What to watch
Early phase / not applicableAnkle Disease, Foot DiseasesRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-01-01 · NCT07289620 · CT.gov ↗
What to watch
Early phase / not applicableHand Injuries and Disorders, Wrist SprainRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-01-01 · NCT07474909 · CT.gov ↗
What to watch
Phase 4Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-01-03 · NCT03829371 · CT.gov ↗
What to watch
Phase 3Relapsed or Refractory Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-01-10 · NCT05519085 · CT.gov ↗
What to watch
Phase 2Subarachnoid Hemorrhage, Aneurysmal, HeadacheRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-01-15 · NCT06008795 · CT.gov ↗
What to watch
Early phase / not applicableHoarseness, Post Operative ComplicaitonRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-01-30 · NCT07722091 · CT.gov ↗
What to watch
Phase 2Esophagus Cancer, Lung CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-01-31 · NCT07617246 · CT.gov ↗
What to watch
February 2027 (8)
Phase 4Postoperative Quality of Recovery, Health-Related Quality-of-Life, Quality of LifeRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-02 · NCT07378215 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-02-01 · NCT04268498 · CT.gov ↗
What to watch
Phase 4Primary HeadacheNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-02-01 · NCT07605065 · CT.gov ↗
What to watch
Phase 2Sickle Cell Disease, Thalassemia, Beta, ThalassemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-02-09 · NCT05736419 · CT.gov ↗
What to watch
Phase 2Recurrent Plasma Cell Myeloma, Refractory Plasma Cell MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-02-14 · NCT04508790 · CT.gov ↗
What to watch
Phase 2Acute Hypoxemic Respiratory FailureRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-02-20 · NCT07334379 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-02-26 · NCT04133636 · CT.gov ↗
What to watch
Phase 4Knee Arthroscopy, Postoperative PainActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-02-26 · NCT07064993 · CT.gov ↗
What to watch
March 2027 (10)
Phase 2Acute Lymphoblastic Leukemia, Philadelphia Chromosome-PositiveActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-03 · NCT04329325 · CT.gov ↗
What to watch
Phase 2Multiple Myeloma, Extramedullary PlasmacytomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-03 · NCT04166565 · CT.gov ↗
What to watch
Phase 2Primary Immune Regulatory Disorder, Autoimmune Lymphoproliferative, Immune System DiseasesRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-03 · NCT05787574 · CT.gov ↗
What to watch
Phase 4Nausea With Vomiting Chemotherapy-InducedRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-03 · NCT04150614 · CT.gov ↗
What to watch
Early phase / not applicableHip FracturesRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-03 · NCT07073209 · CT.gov ↗
What to watch
Phase 1/2Acne VulgarisNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-03-18 · NCT07504822 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-03-22 · NCT03710772 · CT.gov ↗
What to watch
Phase 1/2Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma, Higher-risk Myelodysplastic Syndrome …RecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-03-31 · NCT04068597 · CT.gov ↗
What to watch
Phase 3Relapsed/Refractory Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-03-31 · NCT06508983 · CT.gov ↗
What to watch
Early phase / not applicableArthropathy of Hip, Hip OsteoarthritisRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-03-31 · NCT07584200 · CT.gov ↗
What to watch
April 2027 (14)
Phase 1/2Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-04 · NCT02343042 · CT.gov ↗
What to watch
Phase 3Newly Diagnosed Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-04 · NCT05558319 · CT.gov ↗
What to watch
Early phase / not applicableGlioblastoma, Dexamethasone, SteroidsRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-04 · NCT04266977 · CT.gov ↗
What to watch
Early phase / not applicableSensori-Neural Deafness, ExosomesRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-04 · NCT07568184 · CT.gov ↗
What to watch
Phase 1/2Lymphodepleting Chemotherapy, Myeloid MalignanciesRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-04-01 · NCT06383572 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-04-01 · NCT04835129 · CT.gov ↗
What to watch
Phase 2B Acute Lymphoblastic Leukemia, B Lymphoblastic LymphomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-04-01 · NCT05303792 · CT.gov ↗
What to watch
Phase 2Plasma Cell Myeloma RefractoryActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-04-01 · NCT06356571 · CT.gov ↗
What to watch
Phase 3Plasma Cell MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-04-05 · NCT03319667 · CT.gov ↗
What to watch
Phase 3Primary Immune Thrombocytopenia (ITP)RecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-04-08 · NCT07559331 · CT.gov ↗
What to watch
Phase 1Recurrent Multiple Myeloma, Refractory Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-04-10 · NCT06622005 · CT.gov ↗
What to watch
Phase 2Rosai-Dorfman DiseaseRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-04-12 · NCT07187167 · CT.gov ↗
What to watch
Phase 2Acute Radiation EnteritisNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-04-24 · NCT07548736 · CT.gov ↗
What to watch
Phase 4Total Knee ReplacementRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-04-30 · NCT04432012 · CT.gov ↗
What to watch
May 2027 (12)
Phase 2Colorectal Cancer, Metastatic CancerActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-05 · NCT00492999 · CT.gov ↗
What to watch
Phase 2Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse, RelapseActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-05 · NCT04176718 · CT.gov ↗
What to watch
Phase 2Intrahepatic CholangiocarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-05 · NCT04891289 · CT.gov ↗
What to watch
Phase 3Rheumatic Fever, Sydenham ChoreaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-05 · NCT06259006 · CT.gov ↗
What to watch
Phase 4Lumbar Radiculopathy, Sciatica, Back Pain With RadiationNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-05 · NCT07494136 · CT.gov ↗
What to watch
Phase 4Post Operative Pain, Emergence Agitation, Functional Endoscopic Sinus SurgeryNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-05 · NCT07911202 · CT.gov ↗
What to watch
Phase 2Colon Cancer, Colorectal Cancer, Perioperative Immune ResponseRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-05-01 · NCT07432399 · CT.gov ↗
What to watch
Phase 2Extramedullary Disease in Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-05-01 · NCT06627751 · CT.gov ↗
What to watch
Early phase / not applicablePostoperative Nausea and VomitingRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-05-01 · NCT06988124 · CT.gov ↗
What to watch
Phase 1AL AmyloidosisActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-05-06 · NCT04754945 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-05-31 · NCT06988488 · CT.gov ↗
What to watch
Phase 2Breast Neoplasms, Lung NeoplasmsRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-05-31 · NCT06974604 · CT.gov ↗
What to watch
June 2027 (18)
Phase 1Acute Lymphoblastic LeukemiaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06 · NCT02494882 · CT.gov ↗
What to watch
Phase 1Parotid Neoplasm, Bupivacaine, DexamethasoneRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06 · NCT07812259 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06 · NCT01297764 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06 · NCT02899052 · CT.gov ↗
What to watch
Phase 2Subarachnoid Hemorrhage, Aneurysmal, Headache, Opiate Dependence, Opioid UseRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06 · NCT07294118 · CT.gov ↗
What to watch
Phase 2/3Lassa FeverRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06 · NCT06212336 · CT.gov ↗
What to watch
Phase 3Mature B-cell Non-Hodgkin LymphomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06 · NCT03206671 · CT.gov ↗
What to watch
Phase 4Anterior Cruciate Ligament Reconstruction, Medial Patellofemoral Ligament ReconstructionRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06 · NCT06590402 · CT.gov ↗
What to watch
Early phase / not applicablePostoperative Sore Throat, Cough, HoarsenessNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06 · NCT07760272 · CT.gov ↗
What to watch
Phase 1/2Relapsed and/or Refractory Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06-01 · NCT03715478 · CT.gov ↗
What to watch
Early phase / not applicableSleep DisturbanceNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06-01 · NCT07550803 · CT.gov ↗
What to watch
Phase 1/2Esophageal Squamous Cell CarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06-11 · NCT05319730 · CT.gov ↗
What to watch
Phase 4Pain, Postoperative, Rebound Pain, Shoulder Injuries, Rotator Cuff InjuriesRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06-15 · NCT07699744 · CT.gov ↗
What to watch
Phase 2Multiple Myeloma in Relapse, Multiple Myeloma, RefractoryNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06-30 · NCT05909826 · CT.gov ↗
What to watch
Phase 2Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell LymphomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06-30 · NCT02427620 · CT.gov ↗
What to watch
Phase 4Carbon Monoxide Poisoning, Delayed Neurocognitive SequelaeRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06-30 · NCT06811675 · CT.gov ↗
What to watch
Early phase / not applicablePain, Postoperative, Dexamethasone PalmitateRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06-30 · NCT07341854 · CT.gov ↗
What to watch
Early phase / not applicableOsteoarthritis, Hip, Hip OsteoarthritisRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06-30 · NCT07581470 · CT.gov ↗
What to watch
July 2027 (12)
Phase 1/2Carbon Monoxide Poisoning, Carbon Monoxide Intoxication, Carbon Monoxide Encephalopathy, Carbon Monoxide-induced ParkinsonismNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-07 · NCT06574048 · CT.gov ↗
What to watch
Phase 1/2Relapse Multiple Myeloma, Refractory Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-07 · NCT07479979 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-07 · NCT03556332 · CT.gov ↗
What to watch
Phase 4Oral Mucositis Due to ChemotherapyRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-07 · NCT07287826 · CT.gov ↗
What to watch
Phase 1Relapsed Refractory Multiple Myeloma (RRMM)RecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-07-01 · NCT07032714 · CT.gov ↗
What to watch
Phase 1/2Triple Negative Breast CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-07-01 · NCT04947189 · CT.gov ↗
What to watch
Phase 2Multiple Myeloma, Deletion 17P SyndromeActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-07-01 · NCT04124497 · CT.gov ↗
What to watch
Phase 2Plasmablastic LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-07-01 · NCT04915248 · CT.gov ↗
What to watch
Early phase / not applicableChronic Shoulder Pain, Pericapsular Nerve Group Block (PENG Block), Frozen Shoulder, Bursitis, Rotator Cuff DisordersRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-07-01 · NCT07607691 · CT.gov ↗
What to watch
Phase 2Low Grade Glioma, Malignant Brain Glioma, Malignant Brain Neoplasm, MeningiomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-07-30 · NCT06132685 · CT.gov ↗
What to watch
Phase 1Multiple Myeloma, Refractory Multiple Myeloma, Relapsed Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-07-31 · NCT06348108 · CT.gov ↗
What to watch
Phase 4Hypotension During Cesarean Delivery, Postoperative Nausea and Vomiting (PONV), Pain, PostoperativeEnrolling by invitationStudy of the molecule, not a specific product
Est. primary completion 2027-07-31 · NCT07615595 · CT.gov ↗
What to watch
August 2027 (12)
Phase 1Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-08 · NCT03909412 · CT.gov ↗
What to watch
Phase 1Germ Cell CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-08 · NCT07662200 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-08 · NCT05972135 · CT.gov ↗
What to watch
Phase 2LeukemiaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-08 · NCT01920737 · CT.gov ↗
What to watch
Phase 2AL AmyloidosisActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-08 · NCT03618537 · CT.gov ↗
What to watch
Phase 2/3Newly Diagnosed Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-08 · NCT05665140 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-08 · NCT00572169 · CT.gov ↗
What to watch
Phase 2Sudden Sensorineural Hearing Loss (SSNHL)Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-08-01 · NCT07134075 · CT.gov ↗
What to watch
Phase 2Langerhans Cell Histiocytosis (LCH)Active not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-08-01 · NCT07204041 · CT.gov ↗
What to watch
Phase 2Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia, Recurrent Burkitt Lymphoma …RecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-08-01 · NCT03136146 · CT.gov ↗
What to watch
Phase 2Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma …RecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-08-01 · NCT06550141 · CT.gov ↗
What to watch
Phase 4Pain, Postoperative, Muscle Weakness, Arthroplasty, Replacement, HipRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-08-31 · NCT07855341 · CT.gov ↗
What to watch
September 2027 (14)
Phase 1/2AL AmyloidosisActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09 · NCT05451771 · CT.gov ↗
What to watch
Phase 2Total Knee Replacement, Knee ArthroplastyRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09 · NCT05279092 · CT.gov ↗
What to watch
Phase 2Total Knee Replacement, Knee ArthroplastyRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09 · NCT05736549 · CT.gov ↗
What to watch
Phase 3Out-Of-Hospital Cardiac Arrest, Post-Cardiac Arrest SyndromeActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09 · NCT05895838 · CT.gov ↗
What to watch
Phase 1Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma, Ann Arbor Stage IV Mantle Cell LymphomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09-01 · NCT07444710 · CT.gov ↗
What to watch
Phase 2Smoldering Plasma Cell MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09-01 · NCT04776395 · CT.gov ↗
What to watch
Phase 2Multiple Myeloma in Relapse, Refractory Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09-01 · NCT04790474 · CT.gov ↗
What to watch
Phase 3Multiple Myeloma, New Diagnosis TumorActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09-01 · NCT04096066 · CT.gov ↗
What to watch
Early phase / not applicableKnee OsteoarthritisRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09-01 · NCT07677215 · CT.gov ↗
What to watch
Phase 3Inflammatory ResponseRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09-10 · NCT05323149 · CT.gov ↗
What to watch
Phase 1/2Plasma Cell Myeloma RefractoryRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09-13 · NCT04643002 · CT.gov ↗
What to watch
Phase 4Diabetic Macular Edema (DME)Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09-15 · NCT07438119 · CT.gov ↗
What to watch
Phase 3B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down SyndromeActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09-30 · NCT03914625 · CT.gov ↗
What to watch
Early phase / not applicableOrbital CellulitisNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09-30 · NCT07345819 · CT.gov ↗
What to watch
October 2027 (15)
Phase 2Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10 · NCT00869232 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10 · NCT03004287 · CT.gov ↗
What to watch
Phase 2/3Rib Fractures, Acute Pain, Thoracic TraumaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10 · NCT07827157 · CT.gov ↗
What to watch
Phase 3Postoperative Pain, Total Hip Arthroplasty (THA)Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10 · NCT07847047 · CT.gov ↗
What to watch
Phase 4Sudden Sensorineural Hearing Loss (SSNHL)Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10 · NCT06878599 · CT.gov ↗
What to watch
Phase 4Postoperative Nausea and Vomiting (PONV)Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10 · NCT07360431 · CT.gov ↗
What to watch
Phase 4Radiculopathy, Lumbosacral Region, Back Pain With Radiation, Low Back PainRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10 · NCT05721027 · CT.gov ↗
What to watch
Phase 4Osteoarthritis, Osteoarthritis (OA) of the Knee, Osteoarthritis (OA) of the Shoulder, Osteoarthritis (OA) of the HipRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10 · NCT06603662 · CT.gov ↗
What to watch
Phase 4Preeclampsia, Spinal Anesthesia-Induced Hypotension, Cesarean SectionNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10 · NCT07793760 · CT.gov ↗
What to watch
Early phase / not applicableBrain MetastasesRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10 · NCT07044557 · CT.gov ↗
What to watch
Phase 2Cancer (Solid Tumors), Vomiting, Cisplatin, OlanzapineRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10-01 · NCT07699276 · CT.gov ↗
What to watch
Phase 2Plasma Cell MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10-21 · NCT05208307 · CT.gov ↗
What to watch
Phase 1/2Metastatic Castration-Resistant Prostate CancerActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10-22 · NCT02861573 · CT.gov ↗
What to watch
Phase 2Recurrent Plasma Cell Myeloma, Refractory Plasma Cell MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10-30 · NCT03763162 · CT.gov ↗
What to watch
Phase 2Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia …Active not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10-31 · NCT01424982 · CT.gov ↗
What to watch
November 2027 (11)
Phase 2Leptomeningeal MetastasisRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-11 · NCT06901817 · CT.gov ↗
What to watch
Phase 2Relapsed or Refractory Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-11 · NCT07018050 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-11 · NCT02659293 · CT.gov ↗
What to watch
Early phase / not applicableSpinal Anesthesia, Prolonged Sensory Block, Prolonged Motor BlockNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-11 · NCT07837674 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-11-01 · NCT07918079 · CT.gov ↗
What to watch
Phase 3B Acute Lymphoblastic LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-11-01 · NCT03150693 · CT.gov ↗
What to watch
Phase 4Femoral Neck FracturesRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-11-01 · NCT05023369 · CT.gov ↗
What to watch
Phase 2Malignant NeoplasmRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-11-04 · NCT06979596 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-11-16 · NCT04975997 · CT.gov ↗
What to watch
Phase 1/2Multiple Myeloma RefractoryRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-11-30 · NCT07210047 · CT.gov ↗
What to watch
Phase 4Newly Diagnosed, High Risk, MRD, Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-11-30 · NCT06409702 · CT.gov ↗
What to watch
December 2027 (32)
Phase 1Diabetes (DM)RecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12 · NCT07224334 · CT.gov ↗
What to watch
Phase 1Relapsed Multiple Myeloma, Refractory Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12 · NCT06433947 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12 · NCT04392037 · CT.gov ↗
What to watch
Phase 2Newly Diagnosed Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12 · NCT04891809 · CT.gov ↗
What to watch
Phase 2MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12 · NCT00871013 · CT.gov ↗
What to watch
Phase 2T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, Mixed Phenotype Acute LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12 · NCT06390319 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12 · NCT06742138 · CT.gov ↗
What to watch
Phase 3Multiple Myeloma (MM)RecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12 · NCT07297329 · CT.gov ↗
What to watch
Phase 3AmyloidosisRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12 · NCT07388602 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12 · NCT06158841 · CT.gov ↗
What to watch
Early phase / not applicableCoronary Artery Disease, Aortic Valve DiseaseRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12 · NCT05635227 · CT.gov ↗
What to watch
Phase 3Renal ColicRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-01 · NCT06980727 · CT.gov ↗
What to watch
Phase 4AnalgesiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-01 · NCT05793060 · CT.gov ↗
What to watch
Phase 4Postoperative Pain, Shoulder Arthroscopic SurgeriesNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-01 · NCT07614802 · CT.gov ↗
What to watch
Phase 4Adolescent Idiopathic Scoliosis (AIS)Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-01 · NCT07890220 · CT.gov ↗
What to watch
Phase 2Precursor Cell Lymphoblastic Leukemia-LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-15 · NCT05660473 · CT.gov ↗
What to watch
Phase 2High-risk Smoldering Multiple Myeloma, Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-20 · NCT04775550 · CT.gov ↗
What to watch
Phase 1/2B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative …RecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-25 · NCT01371630 · CT.gov ↗
What to watch
Phase 1MigraineRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-30 · NCT06016465 · CT.gov ↗
What to watch
Phase 3Relapsed or Refractory Multiple Myeloma (RRMM)RecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-30 · NCT06615479 · CT.gov ↗
What to watch
Phase 1Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia …Active not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT03132454 · CT.gov ↗
What to watch
Phase 1NK-Cell Lymphoma, NK-Cell Leukemia, Peripheral T Cell LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT03719105 · CT.gov ↗
What to watch
Phase 1/2Cystoid Macular EdemaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT04225611 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT03376672 · CT.gov ↗
What to watch
Phase 2Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Malignant Solid Neoplasm …Active not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT03583255 · CT.gov ↗
What to watch
Phase 2AL Amyloidosis (AL), t(11;14) PositiveRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT07335887 · CT.gov ↗
What to watch
Phase 2Multiple Myeloma (MM)Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT07811986 · CT.gov ↗
What to watch
Phase 2LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT05645718 · CT.gov ↗
What to watch
Phase 2Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer, Colorectal Neoplasms …RecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT05286814 · CT.gov ↗
What to watch
Phase 2/3Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8RecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT06616584 · CT.gov ↗
What to watch
Phase 3Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT04566328 · CT.gov ↗
What to watch
Early phase / not applicableNephrolithotomy, PercutaneousRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT05024344 · CT.gov ↗
What to watch
2028 (88)
January 2028 (10)
Phase 2POEMS SyndromeRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-01 · NCT07652879 · CT.gov ↗
What to watch
Phase 2Multiple Myeloma, RefractoryRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-01 · NCT04414475 · CT.gov ↗
What to watch
Early phase / not applicableTonsil HypertrophyNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-01 · NCT07299435 · CT.gov ↗
What to watch
Phase 1B-cell Acute Lymphoblastic LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-01-01 · NCT06863259 · CT.gov ↗
What to watch
Phase 1/2Metastatic Appendiceal Adenocarcinoma, Intraperitoneal PaclitaxelRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-01-02 · NCT06207305 · CT.gov ↗
What to watch
Phase 4StomatitisRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-01-04 · NCT07357597 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-01-24 · NCT06106945 · CT.gov ↗
What to watch
Phase 2Primary Immune Thrombocytopenia (ITP)RecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-01-31 · NCT06992128 · CT.gov ↗
What to watch
Phase 2Solid Tumor CancerActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-01-31 · NCT07841210 · CT.gov ↗
What to watch
Phase 3Infant, Premature, Bronchopulmonary Dysplasia (BPD)Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-01-31 · NCT07052201 · CT.gov ↗
What to watch
February 2028 (5)
Phase 2Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-02 · NCT04661137 · CT.gov ↗
What to watch
Phase 3Cervicobrachial NeuralgiaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-02 · NCT07084285 · CT.gov ↗
What to watch
Phase 1Clear Cell Carcinoma, Phase 1, Growth FactorRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-02-01 · NCT07072234 · CT.gov ↗
What to watch
Phase 2Light-chain Cardiac AmyloidosisNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-02-01 · NCT07743957 · CT.gov ↗
What to watch
Phase 2Triple Negative Breast Cancer, Triple Negative Breast Cancer (TNBC), Breast CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-02-08 · NCT07914309 · CT.gov ↗
What to watch
March 2028 (8)
Phase 2Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-03 · NCT05272826 · CT.gov ↗
What to watch
Phase 2/3Multiple Myeloma, Newly DiagnosedRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-03 · NCT06879379 · CT.gov ↗
What to watch
Phase 4Diabetic Macular Edema (DME), Diabetic RetinopathyRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-03 · NCT07843849 · CT.gov ↗
What to watch
Phase 2Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, ph+ Acute Lymphoblastic LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-03-01 · NCT04747912 · CT.gov ↗
What to watch
Phase 2Non-hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma …RecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-03-01 · NCT07763210 · CT.gov ↗
What to watch
Phase 2Relapsed and Refractory Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-03-26 · NCT05530421 · CT.gov ↗
What to watch
Phase 1Multiple Myeloma, Triple Negative Breast Cancer, Duffy Blood Group, Chemokine Receptor Gene Mutation, Duffy Blood Group …RecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-03-31 · NCT07341867 · CT.gov ↗
What to watch
Phase 4Post-Mastectomy Chronic Pain SyndromeRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-03-31 · NCT07556952 · CT.gov ↗
What to watch
April 2028 (4)
Phase 1Trauma InjuryNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-04-01 · NCT07343817 · CT.gov ↗
What to watch
Phase 2Sudden Hearing LossNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-04-20 · NCT07540728 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-04-26 · NCT06353022 · CT.gov ↗
What to watch
Early phase / not applicableLung CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-04-30 · NCT07442890 · CT.gov ↗
What to watch
May 2028 (4)
Phase 2Acute Lymphoblastic Leukemia, Lymphoblastic LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-05 · NCT06533748 · CT.gov ↗
What to watch
Phase 1/2Myeloid MalignanciesRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-05-01 · NCT06930651 · CT.gov ↗
What to watch
Phase 3Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic NeoplasmsRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-05-10 · NCT06136650 · CT.gov ↗
What to watch
Phase 2Ph- Acute Lymphoblastic Leukemia (Ph-ALL)Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-05-31 · NCT07643103 · CT.gov ↗
What to watch
June 2028 (7)
Phase 2Malignant Plasma Cell NeoplasmsNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-06 · NCT07560449 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-06 · NCT03617731 · CT.gov ↗
What to watch
Phase 3Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia, Community Acquired Pneumonia (CAP) …RecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-06 · NCT02735707 · CT.gov ↗
What to watch
Early phase / not applicableParoxysmal Atrial FibrillationRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-06 · NCT07877519 · CT.gov ↗
What to watch
Phase 1Breast Reconstruction, Free Flap ReconstructionRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-06-30 · NCT07891039 · CT.gov ↗
What to watch
Phase 1Recurrent AL Amyloidosis, Refractory AL AmyloidosisActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-06-30 · NCT04847453 · CT.gov ↗
What to watch
Phase 2Down Syndrome, Recurrent B Acute Lymphoblastic LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-06-30 · NCT04546399 · CT.gov ↗
What to watch
July 2028 (10)
Phase 2Facet Joint Pain, Arthropathy, Sacroiliac Joint Dysfunction, Post-neurotomy Neuritis, Chronic PainEnrolling by invitationStudy of the molecule, not a specific product
Est. primary completion 2028-07 · NCT07839195 · CT.gov ↗
What to watch
Phase 2Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified …RecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-07-01 · NCT06905509 · CT.gov ↗
What to watch
Phase 2Lung Cancer, Interstitial Lung DiseaseRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-07-01 · NCT05986318 · CT.gov ↗
What to watch
Phase 2Multiple Myeloma, Relapse Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-07-01 · NCT05789303 · CT.gov ↗
What to watch
Phase 3B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Active not recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-07-01 · NCT04530565 · CT.gov ↗
What to watch
Phase 1Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated …Active not recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-07-02 · NCT05292664 · CT.gov ↗
What to watch
Phase 2Leukemia, Lymphoma, Thalassemia, Aplastic Anemia, Myelodysplastic SyndromesNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-07-03 · NCT07698080 · CT.gov ↗
What to watch
Phase 3Acute Lymphoblastic Leukemia, PediatricRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-07-14 · NCT03643276 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-07-31 · NCT05583617 · CT.gov ↗
What to watch
Phase 2COVID-19Active not recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-07-31 · NCT04488081 · CT.gov ↗
What to watch
August 2028 (9)
Phase 1/2Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-08 · NCT05434689 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-08-01 · NCT06121843 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-08-03 · NCT05714839 · CT.gov ↗
What to watch
Phase 2Asthma (Diagnosis)RecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-08-14 · NCT07455396 · CT.gov ↗
What to watch
Phase 3Non-small Cell Lung Cancer (NSCLC)Active not recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-08-17 · NCT06305754 · CT.gov ↗
What to watch
Phase 1Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Malignant GliomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-08-28 · NCT07791264 · CT.gov ↗
What to watch
Phase 1/2Adenotonsillectomy, Postoperative PainNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-08-30 · NCT07870447 · CT.gov ↗
What to watch
Phase 2Non-Hodgkin's B-cell Lymphoma, Lymphoma Non-Hodgkin, Diffuse Large B-Cell Lymphoma (DLBCL)Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-08-31 · NCT07588698 · CT.gov ↗
What to watch
Phase 3Knee ArthroscopyNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-08-31 · NCT07674576 · CT.gov ↗
What to watch
September 2028 (7)
Phase 2Adult T-cell Leukemia/LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-09-01 · NCT07159620 · CT.gov ↗
What to watch
Phase 3Pain, Postoperative, Liposomal Bupivacaine, Dexamethasone, Supraclavicular Brachial Plexus Block, High Risk Factors, Distal Radial FractureRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-09-01 · NCT07665762 · CT.gov ↗
What to watch
Early phase / not applicableHerpes Zoster PainNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-09-01 · NCT07344246 · CT.gov ↗
What to watch
Phase 4Sudden Sensorineural Hearing LossRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-09-10 · NCT06968507 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-09-15 · NCT05695508 · CT.gov ↗
What to watch
Phase 2/3Primary Central Nervous System LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-09-30 · NCT07185373 · CT.gov ↗
What to watch
Phase 3PneumoniaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-09-30 · NCT04381936 · CT.gov ↗
What to watch
October 2028 (5)
Phase 3Intensive Care PediatricRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-10 · NCT06722118 · CT.gov ↗
What to watch
Phase 2Cushing SyndromeRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-10-01 · NCT06635629 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma, CarcinomatosisRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-10-31 · NCT05977998 · CT.gov ↗
What to watch
Phase 2T Acute Lymphoblastic Leukemia, T Lymphoblastic LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-10-31 · NCT00501826 · CT.gov ↗
What to watch
Phase 3InfluenzaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-10-31 · NCT06528444 · CT.gov ↗
What to watch
November 2028 (6)
Early phase / not applicableBreast Cancer, Postoperative Pain, Chronic Postoperative Pain, Quality of RecoveryNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-11 · NCT07923643 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-11-01 · NCT07786051 · CT.gov ↗
What to watch
Phase 2B Acute Lymphoblastic Leukemia, B Lymphoblastic LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-11-01 · NCT02877303 · CT.gov ↗
What to watch
Phase 2Plasma Cell MyelomaEnrolling by invitationStudy of the molecule, not a specific product
Est. primary completion 2028-11-30 · NCT05669989 · CT.gov ↗
What to watch
Phase 3Prostate Cancer MetastaticRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-11-30 · NCT06136624 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-11-30 · NCT07555938 · CT.gov ↗
What to watch
December 2028 (13)
Phase 1/2Post Operative Pain, Acute, PeriodontitisNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12 · NCT07832110 · CT.gov ↗
What to watch
Phase 1/2Lymphoblastic LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12 · NCT05848687 · CT.gov ↗
What to watch
Phase 3Multiple Myeloma, Relapse Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12 · NCT06561854 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12 · NCT06216158 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12-21 · NCT04910568 · CT.gov ↗
What to watch
Phase 2Immune ThrombocytopeniaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12-30 · NCT07315373 · CT.gov ↗
What to watch
Phase 2Relapsed Cancer, Refractory Multiple Myeloma, Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12-31 · NCT05922501 · CT.gov ↗
What to watch
Phase 2Hemophagocytic LymphohistiocytosesRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12-31 · NCT06160791 · CT.gov ↗
What to watch
Phase 2Acute Lymphoblastic LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12-31 · NCT07301138 · CT.gov ↗
What to watch
Phase 2Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12-31 · NCT06317662 · CT.gov ↗
What to watch
Phase 3AVB - Atrioventricular Block, Fetal AVBActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12-31 · NCT04474223 · CT.gov ↗
What to watch
Phase 4Newly Diagnosed Multiple Myeloma, T(11;14), Sotoclax, CarfilzomibNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12-31 · NCT07709884 · CT.gov ↗
What to watch
Early phase / not applicableDiabetic Macular Edema, Visual Impairment, Diabetes Mellitus, Hyperglycaemia (Diabetic), Oxidative Stress …RecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12-31 · NCT06984822 · CT.gov ↗
What to watch
2029 (35)
January 2029 (6)
Phase 4Orthopedic SurgeriesEnrolling by invitationStudy of the molecule, not a specific product
Est. primary completion 2029-01 · NCT03661645 · CT.gov ↗
What to watch
Phase 2Myeloma MultipleRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-01-11 · NCT07085728 · CT.gov ↗
What to watch
Phase 3Newly Diagnosed Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-01-11 · NCT07764978 · CT.gov ↗
What to watch
Phase 1/2Prostatic Neoplasms, Castration-ResistantActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-01-15 · NCT06353386 · CT.gov ↗
What to watch
Phase 4Lower Respiratory Tract Infection (LRTI), Recurrent WheezingNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-01-30 · NCT07858773 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-01-31 · NCT05438043 · CT.gov ↗
What to watch
February 2029 (4)
Phase 2Relapsed or Refractory Multiple Myeloma (RRMM)Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-02 · NCT07348393 · CT.gov ↗
What to watch
Phase 3Severe BurnsRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-02-07 · NCT06968559 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-02-14 · NCT04923893 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-02-28 · NCT07614360 · CT.gov ↗
What to watch
March 2029 (2)
Phase 2Refractory Multiple Myeloma, Relapsed Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-03-01 · NCT05896228 · CT.gov ↗
What to watch
Phase 2B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-03-30 · NCT06918431 · CT.gov ↗
What to watch
April 2029 (6)
Phase 1Large B-cell Lymphoma, Central Nervous System LymphomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-04 · NCT07608731 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-04 · NCT04822337 · CT.gov ↗
What to watch
Phase 1/2Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent …RecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-04-01 · NCT05658640 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid Tumors, Malignant NeoplasmNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-04-12 · NCT07876128 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-04-13 · NCT07825064 · CT.gov ↗
What to watch
Phase 3Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-04-27 · NCT06824467 · CT.gov ↗
What to watch
May 2029 (3)
Phase 2Newly Diagnosed Multiple Myeloma (NDMM)RecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-05-05 · NCT07891923 · CT.gov ↗
What to watch
Phase 3Relapsed and/or Refractory Multiple Myeloma (RRMM)RecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-05-21 · NCT07222761 · CT.gov ↗
What to watch
Phase 1Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-05-31 · NCT04729114 · CT.gov ↗
What to watch
June 2029 (1)
Phase 1AML - Acute Myeloid LeukemiaEnrolling by invitationStudy of the molecule, not a specific product
Est. primary completion 2029-06 · NCT07014462 · CT.gov ↗
What to watch
July 2029 (1)
Phase 1Type 2 Diabetes, Chronic Kidney DiseasesActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-07-31 · NCT06190158 · CT.gov ↗
What to watch
August 2029 (2)
Phase 3Newly Diagnosed Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-08 · NCT03948035 · CT.gov ↗
What to watch
Phase 4Postoperative Sleep Quality, Postoperative Behaviour, Postoperative Recovery in Children, Postoperative Nausea and Vomiting (PONV) …Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-08-17 · NCT07777276 · CT.gov ↗
What to watch
September 2029 (2)
Phase 3Acute Respiratory Distress Syndrome (ARDS)RecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-09-30 · NCT07576660 · CT.gov ↗
What to watch
Phase 3Hemophagocytic Lymphohistiocytosis (HLH), Secondary Hemophagocytic LymphohistiocytosisNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-09-30 · NCT07861776 · CT.gov ↗
What to watch
November 2029 (1)
Phase 3Multiple Myeloma Refractory, Multiple Myeloma in RelapseRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-11 · NCT07772024 · CT.gov ↗
What to watch
December 2029 (7)
Phase 2Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-12 · NCT05527340 · CT.gov ↗
What to watch
Phase 4Back Pain Lower Back, Neck Pain, Radiculopathy Multiple Sites, Spinal Stenosis Cervicothoracic Region, Spinal Stenosis Lumbar …RecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-12 · NCT07762170 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-12-01 · NCT04240054 · CT.gov ↗
What to watch
Phase 2Multiple Myeloma Refractory, Multiple Myeloma in RelapseRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-12-01 · NCT07096778 · CT.gov ↗
What to watch
Phase 1T-cell Acute Lymphoblastic Leukemia, LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-12-31 · NCT07513129 · CT.gov ↗
What to watch
Phase 1Myeloma, Multiple Myeloma, Refractory Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-12-31 · NCT06518551 · CT.gov ↗
What to watch
Phase 3Smoldering Plasma Cell MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-12-31 · NCT03937635 · CT.gov ↗
What to watch
2030 (20)
January 2030 (1)
Phase 2Multiple Myeloma at First RelapseActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2030-01-01 · NCT04998786 · CT.gov ↗
What to watch
March 2030 (2)
Phase 2B Lymphoblastic LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-03 · NCT06336395 · CT.gov ↗
What to watch
Phase 2Multiple Myeloma, Relapsed/Refractory Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-03 · NCT07284758 · CT.gov ↗
What to watch
April 2030 (2)
Phase 3Lymphoblastic Lymphoma, ChildhoodRecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-04-22 · NCT04043494 · CT.gov ↗
What to watch
Phase 1/2Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, Pediatric Cancer, Pediatric ALL …Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2030-04-30 · NCT07770698 · CT.gov ↗
What to watch
June 2030 (1)
Phase 4Adhesive Small Bowel ObstructionRecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-06 · NCT07084441 · CT.gov ↗
What to watch
July 2030 (4)
Phase 2Hodgkin Lymphoma, Advanced Hodgkin LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-07-15 · NCT07002216 · CT.gov ↗
What to watch
Phase 3AL AmyloidosisRecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-07-29 · NCT06022939 · CT.gov ↗
What to watch
Phase 2Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL), LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-07-31 · NCT07227584 · CT.gov ↗
What to watch
Phase 3Dengue, Severe Dengue, Mosquito-Borne Diseases, Vector Borne Diseases, Arbovirus Infections, Flavivirus Infections, RNA Virus Infections …Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2030-07-31 · NCT07543458 · CT.gov ↗
What to watch
August 2030 (2)
Phase 1/2Solid TumorRecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-08-08 · NCT04300556 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-08-30 · NCT07227311 · CT.gov ↗
What to watch
September 2030 (3)
Phase 2Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2030-09-02 · NCT06577025 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-09-30 · NCT06997081 · CT.gov ↗
What to watch
Phase 3Tick-Borne EncephalitisRecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-09-30 · NCT07584525 · CT.gov ↗
What to watch
October 2030 (2)
Phase 2MedulloblastomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2030-10 · NCT07856069 · CT.gov ↗
What to watch
Phase 3Plasma Cell MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2030-10-14 · NCT04270409 · CT.gov ↗
What to watch
December 2030 (3)
Phase 1/2Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-12 · NCT06953960 · CT.gov ↗
What to watch
Phase 2Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant Ineligible, Newly Diagnosed Multiple Myeloma (NDMM)Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2030-12-01 · NCT07247097 · CT.gov ↗
What to watch
Phase 3Breast Cancer, Interstitial Lung Disease (ILD)Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2030-12-20 · NCT07828054 · CT.gov ↗
What to watch
2031 (17)
January 2031 (1)
Phase 3Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2031-01 · NCT06187441 · CT.gov ↗
What to watch
February 2031 (2)
Phase 1/2Pediatric CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2031-02 · NCT02813135 · CT.gov ↗
What to watch
Phase 2Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements …RecruitingStudy of the molecule, not a specific product
Est. primary completion 2031-02-22 · NCT03418038 · CT.gov ↗
What to watch
March 2031 (1)
Phase 2Prostate Cancer (Adenocarcinoma), Metastatic Prostate CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2031-03-30 · NCT06616597 · CT.gov ↗
What to watch
April 2031 (3)
Phase 1/2Recurrent Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2031-04-01 · NCT06785415 · CT.gov ↗
What to watch
Phase 2Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative …Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2031-04-16 · NCT07636564 · CT.gov ↗
What to watch
Phase 3Multiple Myeloma, Newly Diagnosed Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2031-04-28 · NCT06679101 · CT.gov ↗
What to watch
May 2031 (3)
Phase 2Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2031-05 · NCT03314181 · CT.gov ↗
What to watch
Phase 2/3B-cell Non Hodgkin LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2031-05-01 · NCT05991388 · CT.gov ↗
What to watch
Phase 3Plasma Cell MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2031-05-30 · NCT05561387 · CT.gov ↗
What to watch
June 2031 (1)
Phase 2/3Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2031-06-01 · NCT04513639 · CT.gov ↗
What to watch
July 2031 (1)
Phase 1Ovarian Neoplasms, Endometrial NeoplasmsNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2031-07-05 · NCT07870278 · CT.gov ↗
What to watch
August 2031 (1)
Phase 1Multiple MyelomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2031-08-22 · NCT07609706 · CT.gov ↗
What to watch
September 2031 (1)
Phase 2Advanced Solid Tumors, Malignant NeoplasmRecruitingStudy of the molecule, not a specific product
Est. primary completion 2031-09-30 · NCT07785609 · CT.gov ↗
What to watch
October 2031 (1)
Phase 1/2Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent …Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2031-10-01 · NCT07175415 · CT.gov ↗
What to watch
November 2031 (1)
Phase 3Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2031-11 · NCT07285239 · CT.gov ↗
What to watch
December 2031 (1)
Phase 2Multiple Myeloma Refractory, Multiple Myeloma in RelapseNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2031-12 · NCT07901868 · CT.gov ↗
What to watch
2032 (10)
January 2032 (2)
Phase 4Allogeneic Granulocyte DonationRecruitingStudy of the molecule, not a specific product
Est. primary completion 2032-01-01 · NCT01553214 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2032-01-31 · NCT06182774 · CT.gov ↗
What to watch
February 2032 (3)
Phase 1/2Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent …RecruitingStudy of the molecule, not a specific product
Est. primary completion 2032-02-01 · NCT05745714 · CT.gov ↗
What to watch
Phase 1/2Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent …RecruitingStudy of the molecule, not a specific product
Est. primary completion 2032-02-01 · NCT05751044 · CT.gov ↗
What to watch
Phase 2Lung Neoplasm MalignantActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2032-02-06 · NCT06788912 · CT.gov ↗
What to watch
March 2032 (1)
Phase 3B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia …RecruitingStudy of the molecule, not a specific product
Est. primary completion 2032-03-31 · NCT03959085 · CT.gov ↗
What to watch
June 2032 (1)
Phase 1/2Metastatic Castration-resistant Prostate CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2032-06-29 · NCT07908524 · CT.gov ↗
What to watch
July 2032 (1)
Phase 4Arthroplasty, Replacement, ShoulderRecruitingStudy of the molecule, not a specific product
Est. primary completion 2032-07-31 · NCT04507412 · CT.gov ↗
What to watch
November 2032 (2)
Phase 2Smouldering MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2032-11-01 · NCT06762769 · CT.gov ↗
What to watch
Phase 2Plasma Cell LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2032-11-06 · NCT07605416 · CT.gov ↗
What to watch
2033 (13)
January 2033 (1)
Phase 2AmyloidosisRecruitingStudy of the molecule, not a specific product
Est. primary completion 2033-01-12 · NCT07224672 · CT.gov ↗
What to watch
March 2033 (1)
Phase 2Relapsed / Refractory Multiple MyelomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2033-03 · NCT07748689 · CT.gov ↗
What to watch
May 2033 (1)
Phase 2Multiple Myeloma, CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2033-05-28 · NCT05145400 · CT.gov ↗
What to watch
June 2033 (3)
Phase 3Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2033-06 · NCT05257083 · CT.gov ↗
What to watch
Phase 3Leukemia, Acute LymphoblasticRecruitingStudy of the molecule, not a specific product
Est. primary completion 2033-06 · NCT04307576 · CT.gov ↗
What to watch
Phase 2Natural Killer/T-cell LymphomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2033-06-30 · NCT07768943 · CT.gov ↗
What to watch
August 2033 (1)
Phase 2/3Multiple Myeloma (MM)Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2033-08-01 · NCT07887984 · CT.gov ↗
What to watch
September 2033 (2)
Phase 1Relapsed/Refractory Multiple MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2033-09 · NCT05259839 · CT.gov ↗
What to watch
Phase 1/2Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive …RecruitingStudy of the molecule, not a specific product
Est. primary completion 2033-09-19 · NCT07387926 · CT.gov ↗
What to watch
October 2033 (2)
Phase 3Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2033-10-01 · NCT07624513 · CT.gov ↗
What to watch
Phase 2/3B-cell Acute Lymphoblastic LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2033-10-18 · NCT07570173 · CT.gov ↗
What to watch
November 2033 (1)
Phase 2Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Hematologic MalignanciesRecruitingStudy of the molecule, not a specific product
Est. primary completion 2033-11-16 · NCT07709000 · CT.gov ↗
What to watch
December 2033 (1)
Phase 2Lymphoblastic Leukemia in ChildrenRecruitingStudy of the molecule, not a specific product
Est. primary completion 2033-12-31 · NCT06099366 · CT.gov ↗
What to watch
2034 (2)
January 2034 (1)
Phase 2LymphomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2034-01-31 · NCT02106988 · CT.gov ↗
What to watch
May 2034 (1)
Phase 4Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Mixed Phenotype Acute LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2034-05 · NCT06289673 · CT.gov ↗
What to watch
2035 (2)
September 2035 (1)
Phase 2/3Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma, Stage IV T Lymphoblastic Leukemia/Lymphoma …Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2035-09-01 · NCT07072585 · CT.gov ↗
What to watch
December 2035 (1)
Phase 1/2Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2035-12 · NCT06892522 · CT.gov ↗
What to watch
2036 (3)
May 2036 (1)
Phase 3Multiple Myeloma, Newly DiagnosedRecruitingStudy of the molecule, not a specific product
Est. primary completion 2036-05 · NCT06918002 · CT.gov ↗
What to watch
September 2036 (1)
Phase 1/2Myeloma Multiple, MyelomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2036-09-30 · NCT07600151 · CT.gov ↗
What to watch
December 2036 (1)
Phase 3Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2036-12 · NCT06932562 · CT.gov ↗
What to watch
2039 (1)
March 2039 (1)
Phase 3Newly Diagnosed Multiple MyelomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2039-03 · NCT07903506 · CT.gov ↗
What to watch
2042 (1)
February 2042 (1)
Phase 3Newly Diagnosed Multiple MyelomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2042-02 · NCT07887672 · CT.gov ↗
What to watch

See the full readout calendar ↗